Autosomal Dominant Nonsyndromic Hearing Loss 7

Mendelian MONDO:0011074 Pathograph 16 Show in embeddings browser Autosomal Dominant Nonsyndromic Hearing Loss

DFNA7 is LMX1A-related autosomal dominant nonsyndromic sensorineural hearing loss, sometimes accompanied by vestibular dysfunction. Onset ranges from congenital to adult, severity from mild to profound, and hearing can be symmetric or asymmetric within the same family. Progressive loss is documented, but neither normal newborn hearing nor universally normal inner-ear imaging should be assumed. Haploinsufficiency is the favored molecular explanation for studied dominant alleles, supported by reduced reporter transactivation and allele-specific functional work. The relevant cochlear targets, affected cell populations and balance between developmental defects and postdevelopmental dysfunction remain unresolved. Homozygous functional-null mice establish developmental roles in the inner ear and central auditory system; they do not reproduce the endogenous heterozygous patient genotype. A separately reported recessive LMX1A phenotype is discussed as an allelic boundary, not a second inheritance mode of this dominant entry.

Ask OpenScientist

Ask a research question about Autosomal Dominant Nonsyndromic Hearing Loss 7. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
5
Pathophys.
6
Phenotypes
1
Hypotheses
3
Gaps
16
Pathograph
1
Genes
4
Medical Actions
1
Datasets
5
Models
19
References
1
Deep Research
👪

Inheritance

1
Autosomal dominant HP:0000006
Heterozygous pathogenic LMX1A variants segregate through multiple generations; de novo variants also occur. Expressivity varies substantially within families. A heterozygous parent can transmit the variant to half of offspring, but this does not predict age at onset or severity.
Autosomal dominant inheritance
Show evidence (4 references)
PMID:29754270 SUPPORT Human Clinical
"Here, we identified heterozygous pathogenic missense variants of LMX1A in two families of Dutch origin with progressive nonsyndromic hearing impairment (HI), using whole exome sequencing."
The founding dominant families and the heterozygous state of the alleles.
PMID:29754270 SUPPORT Human Clinical
"One variant, c.721G > C (p.Val241Leu), occurred de novo and is predicted to affect the homeodomain of LMX1A, which is essential for DNA binding."
The authors inferred de novo p.Val241Leu in subject II:7 from haplotypes shared with noncarrier siblings; this is distinct from direct testing of both parents.
PMID:36519758 SUPPORT Human Clinical
"This C-terminal frameshift mutation co-segregated with autosomal dominant (AD) NSHL in a four-generation Chinese family"
Four-generation cosegregation of a truncating allele with dominant disease.
+ 1 more reference
◈

Mechanistic Hypotheses

1
LMX1A dysfunction may impair auditory cellular homeostasis
lmx1a_cellular_stress EMERGING
Evidence balance 3 support
RNA sequencing and exploratory DIA proteomics compared mutant and wild-type Lmx1a overexpression in HEI-OC1 cells. Enrichment implicated immune signaling, ER stress, ionic/metabolic regulation and synaptic programs. These are cell-line signatures, not demonstrated inflammation, excitotoxicity, infection or necroptosis in DFNA7 patients. The authors explicitly acknowledge nonspecific responses to artificial overexpression. Earlier C-terminal-domain apoptosis assays indicate a role in survival regulation but, in the accessible abstract, do not establish increased patient hair-cell death. Native-cell perturbation and rescue are needed to assign downstream causal steps.
Show evidence (3 references)
PMID:42253511 SUPPORT In Vitro
"This dual‐validation approach revealed synchronized enrichment in proteostasis and ER stress networks"
Integrated RNA/protein enrichment provides an exploratory mechanistic lead.
PMID:42253511 SUPPORT In Vitro
"we cannot preclude the possibility that these alterations partially reflect an intrinsic, nonspecific response of the artificial HEI‐OC1 overexpression system to in vitro manipulation."
The study’s explicit limitation prevents promoting these signatures to patient mechanisms.
PMID:36519758 SUPPORT In Vitro
"Furthermore, apoptosis assays suggested that the C-terminal domain of the LMX1A was important for mediating apoptosis in the cochlear hair cells."
Accessible abstract supports a C-terminal role in apoptosis assays; it does not establish increased apoptosis in human cochlear hair cells.
?

Discussions and Knowledge Gaps

3
Which endogenous heterozygous LMX1A alleles reproduce human hearing loss, and do developmental and postdevelopmental requirements differ?
HUMAN MODEL MISMATCH OPEN lmx1a_dominant_model_gap
Attached to
pathophysiology#Cochleovestibular Dysfunction animal_models#Lmx1a mutanlallemand and Belly Spot and Deafness mice animal_models#Lmx1a drJ functional-null mouse
Young heterozygous mtl/bsd mice had normal hearing, while biallelic mutants had major malformations. The 2025 drJ study includes heterozygote EP measurements, and the 2026 central study includes double heterozygotes. These are informative negative or comparator observations, not lifelong exclusions. Human onset includes congenital and adult cases. Serial heterozygous patient-allele knock-in studies could establish a closer model; temporally controlled perturbation and rescue are needed to distinguish developmental from ongoing requirements.
Proposed experiments
Patient-allele knock-in and temporally controlled Lmx1a studies
exp_dfna7_aged_heterozygous_lmx1a_abr
Compare heterozygous patient-allele knock-ins with null heterozygotes and wild-type littermates through aging, with ABR/DPOAE, strial physiology and histology. Use embryonic versus postdevelopmental perturbation and rescue to test timing. Late decline alone cannot distinguish subtle developmental injury from an ongoing requirement.
Readouts
Longitudinal auditory thresholds
pathophysiology#Cochleovestibular Dysfunction
Interpretation: Defines allele- and age-dependent dysfunction; normal results constrain the particular model without excluding human disease.
Response to temporally restricted perturbation and rescue
pathophysiology#Cochleovestibular Dysfunction
Interpretation: Timing-dependent phenotypes and rescue would distinguish developmental from ongoing requirements more directly than endpoint histology.
Show evidence (3 references)
PMID:23226461 SUPPORT Model Organism
"The analysis of auditory brainstem responses (ABR) showed that mtl and bsd homozygotes are deaf, whereas heterozygous and wildtype littermates have normal hearing."
Normal heterozygous ABR at tested ages; no species-wide or lifelong conclusion follows.
PMID:29754270 SUPPORT Human Clinical
"Although Lmx1a mouse mutants demonstrate neurological, skeletal, pigmentation and reproductive system abnormalities, no syndromic features were present in the participating subjects of either family."
No syndromic findings in these participating families, despite broader null-mouse phenotypes.
PMID:29754270 SUPPORT Human Clinical
"Alternatively, minor cochleovestibular developmental abnormalities could eventually lead to the progressive phenotype seen in the families."
A competing developmental interpretation retained by the founding authors.
What contributes to interaural asymmetry and intrafamilial variability in LMX1A-related hearing loss?
KNOWLEDGE GAP OPEN lmx1a_asymmetry_mechanism
Attached to
phenotypes#Asymmetric Sensorineural Hearing Loss pathophysiology#Cochleovestibular Dysfunction
A germline variant does not by itself explain differences between ears or relatives. Developmental variation, local cellular responses, age and additional genetic or acquired factors are candidates, not established causes. The 2026 study proposes stress-related asymmetry but lacks longitudinal audiometry and imaging of other affected relatives; the 2022 series also describes fluctuation with possible Meniere disease in one carrier. Neither observation proves a shared modifier. Prospective ear-specific assessment is needed.
Show evidence (2 references)
PMID:35711095 SUPPORT Human Clinical
"It is important to note that asymmetric hearing loss was identified in all probands and most affected individuals, although the extent of asymmetry varied."
Establishes the phenomenon as near-universal in the series while explicitly noting that its degree varies, which is the variability the gap is about.
PMID:42253511 SUPPORT Human Clinical
"Clinical manifestations exhibited significant intrafamilial phenotypic variability, with hearing loss (HL) severity ranging from mild to profound, and onset varying from infancy to mid-adulthood."
Between-individual variability on one allele within one family, the same puzzle as between-ear asymmetry seen at a different scale, and equally unexplained by dosage.
Has the molecular cause of the original Norwegian DFNA7 linkage family been identified?
KNOWLEDGE GAP OPEN dfna7_locus_to_gene_assignment
Attached to
disease#Autosomal Dominant Nonsyndromic Hearing Loss 7 genetic#LMX1A
The 1996 study mapped a 22-cM interval on 1q21-q23 without identifying a causal variant. The retrieved later LMX1A reports establish the dominant gene–disease relationship in other families, and ClinGen classified it as definitive in 2025. They do not solve the original Norwegian pedigree. High-frequency hearing loss in that family is compatible with later LMX1A presentations and is not evidence for a different disease.
Show evidence (5 references)
PMID:8842739 SUPPORT Human Clinical
"Analysis of recombinant individuals maps the deafness gene (DFNA7) to a 22 cM region between D1S104 and D1S466."
The locus definition. A 22 cM interval is what the DFNA7 label originally denoted, and the founding paper stops at localisation.
PMID:8842739 SUPPORT Human Clinical
"The region contains several attractive candidate genes."
The founding authors' own statement that the interval held multiple candidates, which is why positional plausibility alone does not settle the assignment.
PMID:8842739 SUPPORT Human Clinical
"The present report describes a large Norwegian family with autosomal dominant non-syndromic, progressive high tone hearing loss with linkage to 1q21-q23."
The original high-tone progressive phenotype overlaps later LMX1A families; it is not a phenotypic contradiction.
+ 2 more references
⚙

Pathophysiology

5
LMX1A Haploinsufficiency
Dominant disease alleles reduce functional LMX1A activity through heterogeneous lesions, including impaired DNA binding, truncation and, for p.Phe135LeufsTer3, faster decay of transfected mutant RNA. Functional insufficiency does not mean every missense variant lowers protein abundance. Reporter titration favors haploinsufficiency for the tested alleles but does not exclude every alternative effect in native cochlear cells. The 2026 Actinomycin D assay measures RNA stability in transfected HEI-OC1 cells; the authors interpret this as nonsense-mediated decay, without directly testing the surveillance pathway in patient cochlear tissue. No augmentation treatment is established by these experiments.
LMX1A hgnc:6653 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves LMX1A (hgnc:6653). hgnc:6653 is a gene from the HUGO Gene Nomenclature Committee.
Genetic context LMX1A hgnc:6653 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns LMX1A (hgnc:6653). hgnc:6653 is a gene from the HUGO Gene Nomenclature Committee. variant_origin: GERMLINE zygosity: HETEROZYGOUS functional_impact_category: LOSS_OF_FUNCTION
Functional insufficiency is favored for studied pathogenic dominant alleles; reported VUSs and the recessive p.Ile369Thr allele require separate interpretation.
Downstream
Reduced Transactivation of LMX1A Target Genes
Show evidence (3 references)
PMID:42253511 SUPPORT In Vitro
"Furthermore, plasmid titration experiments and Actinomycin D chase assays functionally corroborated the haploinsufficiency mechanism and excluded the dominant-negative effect."
The authors’ mechanistic interpretation of plasmid titration and RNA-decay assays for p.Phe135LeufsTer3; conclusions are bounded by the transfected cell systems and tested allele.
PMID:32840933 SUPPORT In Vitro
"Further, our dominant LMX1A variant exerted pathogenic effects via haploinsufficiency rather than dominant-negative effect."
Functional study of p.Arg199Gly favored haploinsufficiency; this does not establish identical behavior for every allele.
PMID:35254497 SUPPORT In Vitro
"We also provide further evidence for haploinsufficiency as the pathogenic mechanism underlying LMX1A-related ADHL."
Additional functional evidence for p.Ala229Asp; overlapping investigators and similar reporter approaches do not constitute three fully independent model systems.
Reduced Transactivation of LMX1A Target Genes
Several dominant LMX1A variants reduce reporter transactivation. The 2026 HEK293 assay used an INS-promoter luciferase construct and found reduced activity for five dominant variants, whereas recessive p.Ile369Thr retained wild-type-like activity. These assays do not identify native auditory targets. Homeodomain and C-terminal changes can impair protein–DNA interaction; a structural study of WNT1/PITX3 promoter recognition and neuronal cells supplies additional noncochlear evidence. A proposed activity–severity correlation from a small allele comparison is not a validated predictor of individual prognosis, especially given wide intrafamilial variability.
DNA-binding transcription factor activity GO:0003700 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased DNA-binding transcription factor activity (GO:0003700). GO:0003700 is a molecular function from the Gene Ontology.
Experimental models
HEK293 LMX1A transactivation reporter CELL LINE Directly measures reporter transactivation in a nonauditory cell line.
Downstream
Cochleovestibular Dysfunction The intervening auditory transcriptional program and affected cell populations are incompletely resolved.
Show evidence (6 references)
PMID:35711095 SUPPORT In Vitro
"Compared with the wild-type protein, all mutant LMX1A proteins had significantly reduced transactivation efficiency, indicating that the ability to elicit transcription of the downstream target genes of LMX1A was severely compromised."
Reduced transactivation in the tested variants, including p.Gln240Arg, which remained a VUS in that publication; an assay effect alone does not establish pathogenicity.
PMID:32840933 SUPPORT In Vitro
"Resultantly, p.Arg199Gly manifesting the most severe NSHL showed the biggest reduction of transcriptional activity in contrast with moderately reduced activity of p.Cys97Ser and p.Val241Leu associated with less severe progressive NSHL, proposing a genotype-phenotype correlation."
A proposed correlation across a small allele comparison; clinical severity is not a calibrated dose-response and varies within families.
PMID:35254497 SUPPORT In Vitro
"and one family with a novel variant in LMX1A (c.686C>A; p.(Ala229Asp)) that impairs its transcriptional activity"
A further allele independently shown to impair transcriptional activity.
+ 3 more references
Impaired Strial Differentiation
Mechanism confidence: Hypothetical
Homozygous Lmx1a functional-null mice fail to establish normal marginal/intermediate strial layers. This demonstrates a developmental strial requirement in that model. A corresponding differentiation defect in human heterozygotes is hypothetical. Disappearance of cochlear melanoblast labeling was observed, but cell death versus altered recruitment or migration was not resolved by lineage tracing.
Animal models
Lmx1a drJ functional-null mouse Mouse partially recapitulates Establishes the null-model strial phenotype underlying the candidate human mechanism.
Downstream
Reduced Endocochlear Potential Defective strial formation accompanies failure to establish the normal endocochlear potential in the homozygous mouse; the human branch remains hypothetical.
Show evidence (1 reference)
PMID:40109362 SUPPORT INDIRECT Model Organism
"we observe a lack of proteins specific to the stria vascularis, such as BSND and KCNQ1 in marginal cells and CD44 in intermediate cells."
Strial differentiation-marker loss in the homozygous model.
Reduced Endocochlear Potential
Mechanism confidence: Hypothetical
Homozygous functional-null mice have endocochlear potentials below 6 mV at P12 and P21. Whether subtler strial physiology mediates dominant human hearing loss remains hypothetical. The 2025 experiment includes wild-type, heterozygous and homozygous animals, so absence of heterozygote measurements cannot be claimed.
Animal models
Lmx1a drJ functional-null mouse Mouse partially recapitulates Measures endocochlear-potential failure in the homozygous functional-null model.
Downstream
Cochleovestibular Dysfunction The null-model physiology suggests a candidate auditory mechanism; mediation in human heterozygotes is untested.
Show evidence (1 reference)
PMID:40109362 SUPPORT INDIRECT Model Organism
"we measured the EP at P12 (during development) and P21 (mature EP) and confirmed a total absence of EP remained at less than 6-mV"
The source calls EP absent but reports a residual measurement below 6 mV, not exact mathematical zero.
Cochleovestibular Dysfunction
Mechanism confidence: Provisional
Heterozygous LMX1A disease can impair cochlear and vestibular function through pathways that remain incompletely resolved. An ongoing maintenance requirement and subtle developmental defects are plausible and may coexist. Congenital cases and cochlear-aperture stenosis in one 2026 proband prevent a universal postdevelopmental-only model. Lmx1a expression becomes restricted to nonsensory epithelia during ear development, so a mature hair-cell-autonomous transcriptional defect should not be assumed. Clinical imaging and progression alone do not distinguish the alternatives.
Animal models
Lmx1a mutanlallemand and Belly Spot and Deafness mice Mouse partially recapitulates Models loss of cochleovestibular function after biallelic disruption; does not reproduce the patient heterozygous genotype.
Lmx1a and Lmx1b central auditory allelic series Mouse partially recapitulates Demonstrates an additional central developmental requirement for Lmx1a, with partial Lmx1b redundancy.
Downstream
Progressive Sensorineural Hearing Impairment
Vestibular Dysfunction
Congenital Severe-to-Profound Sensorineural Hearing Impairment
Postlingual Sensorineural Hearing Impairment
Asymmetric Sensorineural Hearing Loss
Downsloping High-Frequency Audiogram Configuration
Show evidence (5 references)
PMID:29754270 SUPPORT Human Clinical
"We propose that a single LMX1A wild-type copy is sufficient for normal development but insufficient for maintenance of cochleovestibular function."
The original authors’ maintenance hypothesis, not a demonstrated universal sequence.
PMID:29754270 SUPPORT Human Clinical
"The late-onset progressive phenotype and the absence of cochleovestibular malformations on computed tomography scans indicate that heterozygous defects of LMX1A do not result in severe developmental abnormalities in humans."
Normal labyrinth imaging in the examined founding-family subjects; other relatives and subsequent congenital presentations prevent generalization to all patients.
PMID:29754270 SUPPORT Human Clinical
"Alternatively, minor cochleovestibular developmental abnormalities could eventually lead to the progressive phenotype seen in the families."
The authors explicitly retain a subtle developmental alternative; postdevelopmental maintenance was not established.
+ 2 more references
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Autosomal Dominant Nonsyndromic Hearing Loss 7 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Progressive Sensorineural Hearing Impairment Auditory HP:0000408 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Progressive sensorineural hearing impairment (HP:0000408). HP:0000408 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:29754270 SUPPORT Human Clinical
"Here, we identified heterozygous pathogenic missense variants of LMX1A in two families of Dutch origin with progressive nonsyndromic hearing impairment (HI), using whole exome sequencing."
Progressive nonsyndromic hearing impairment in the founding families.
PMID:42253511 SUPPORT Human Clinical
"cosegregating with progressive and asymmetric sensorineural hearing loss"
The 2026 family is described as progressive, but the paper explicitly lacks longitudinal audiograms; observed longitudinal progression is supported by other pedigrees.
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT INDIRECT REVIEW SYNTHESIS Other
"In general, autosomal dominant nonsyndromic hearing loss is postlingual, progressive, and high frequency."
General dominant nonsyndromic hearing-loss pattern; DFNA7 also includes congenital, symmetric and atypical presentations.
Asymmetric Sensorineural Hearing Loss Auditory HP:0000407 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Asymmetric sensorineural hearing impairment, annotated with Sensorineural hearing impairment (HP:0000407). HP:0000407 is a phenotype from the Human Phenotype Ontology.
Asymmetry is represented using the sensorineural hearing-impairment term with the interaural pattern specified in prose. Frequencies differ across small, partially overlapping cohorts: two of seven founding-family subjects were asymmetric, and a later Korean series reported five of nine. That paper uses >10 dB in methods and >15 dB in results. A uniform population frequency or universal asymmetry is therefore not asserted.
Show evidence (7 references)
PMID:35711095 SUPPORT Human Clinical
"It is important to note that asymmetric hearing loss was identified in all probands and most affected individuals, although the extent of asymmetry varied."
The primary observation, with its own caveat about varying extent.
PMID:35711095 SUPPORT Human Clinical
"For the first time, we suggest that LMX1A is one of the candidate genes which, if altered, could be associated with dominantly inherited asymmetric hearing loss."
The diagnostic implication the authors draw.
PMID:42253511 SUPPORT Human Clinical
"cosegregating with progressive and asymmetric sensorineural hearing loss"
Independent replication of asymmetry in a Chinese family.
+ 4 more references
Downsloping High-Frequency Audiogram Configuration Auditory HP:0001757 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is High-frequency sensorineural hearing impairment (HP:0001757). HP:0001757 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:29754270 SUPPORT Human Clinical
"Affected subjects had mild to profound HI with overall a downsloping audiogram configuration"
The audiogram configuration across the founding families, with its severity range.
PMID:42253511 SUPPORT Human Clinical
"Individual II: 2 exhibited high‐frequency SNHL with no documented history of exposure to known ototoxic agents."
High-frequency loss in an independent family, with ototoxic exposure explicitly excluded, which matters because the same audiogram shape is the signature of acquired causes.
Vestibular Dysfunction Vestibular HP:0001751 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal vestibular function (HP:0001751). HP:0001751 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:29754270 SUPPORT Human Clinical
"About half of the affected individuals displayed vestibular dysfunction and experienced symptoms thereof."
The abstract summarizes vestibular involvement loosely; the full text distinguishes symptoms in four subjects from testing in three, including an asymptomatic subject.
PMID:29754270 SUPPORT Human Clinical
"cVEMPs showed no responses up to 100 dBnHL in both subjects, indicating dysfunction of the saccule."
Localises the deficit to the saccule rather than leaving it at organ level, which is the kind of detail that distinguishes a measured vestibular phenotype from a reported symptom.
Congenital Severe-to-Profound Sensorineural Hearing Impairment Auditory HP:0008527 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Congenital sensorineural hearing impairment (HP:0008527). HP:0008527 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:32840933 SUPPORT Human Clinical
"identification of a de novo, heterozygous, missense variant (c.595A > G; p.Arg199Gly) located in the homeodomain of LMX1A in a subject with congenital severe-to-profound deafness through Exome sequencing"
The congenital severe-to-profound case and the allele responsible.
PMID:36519758 SUPPORT Human Clinical
"In this family, the affected individuals exhibited the variable auditory phenotypes ranging from profound congenital deafness at birth or to mild/moderate HL in adulthood."
Congenital profound deafness at one end of a single family's range, which is also the clearest statement of how wide intrafamilial variability is.
Postlingual Sensorineural Hearing Impairment Auditory HP:0008596 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Postlingual sensorineural hearing impairment (HP:0008596). HP:0008596 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42253511 SUPPORT Human Clinical
"Clinical manifestations exhibited significant intrafamilial phenotypic variability, with hearing loss (HL) severity ranging from mild to profound, and onset varying from infancy to mid-adulthood."
Documents onset extending to mid-adulthood, and the intrafamilial spread that makes prognosis from an affected relative unreliable.
🧬

Genetic Associations

1
LMX1A
Gene: LMX1A hgnc:6653 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is LMX1A (hgnc:6653). hgnc:6653 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (5 references)
PMID:42253511 SUPPORT Human Clinical
"Pathogenic variants in the LIM-homeodomain transcription factor LMX1A represent a rare yet critical etiology for autosomal dominant nonsyndromic hearing loss 7 (DFNA7) and less frequently, its autosomal recessive counterpart (ARNSHL)."
The gene-disease relationship, and the existence of a recessive counterpart.
CGGV:assertion_163f8708-7d3b-424a-826a-76e37260745c-2025-04-22T160000.000Z SUPPORT REVIEW SYNTHESIS Other
"there is definitive evidence supporting the relationship between LMX1A and autosomal dominant nonsyndromic deafness."
ClinGen Hearing Loss GCEP classification approved at the 16 April 2025 meeting and recorded 22 April 2025; this concerns the dominant gene–disease relationship.
PMID:41078281 SUPPORT Human Clinical
"Genetic testing revealed a variant of uncertain significance (p.Val241Ala) in LMX1A"
Candidate allele observed in affected father and son; preserve the reported uncertainty.
+ 2 more references
🗃️

External Assertions

1
ClinGen LMX1A dominant hearing-loss validity
ClinGen gene disease validity HGNC:6653
Definitive association; April 2025 curation.
Show evidence (1 reference)
CGGV:assertion_163f8708-7d3b-424a-826a-76e37260745c-2025-04-22T160000.000Z SUPPORT REVIEW SYNTHESIS Other
"there is definitive evidence supporting the relationship between LMX1A and autosomal dominant nonsyndromic deafness."
ClinGen Hearing Loss GCEP classification approved at the 16 April 2025 meeting and recorded 22 April 2025; this concerns the dominant gene–disease relationship.
💊

Medical Actions

4
Hearing Amplification
Platform: Device
Fit and adjust hearing aids according to ear-specific thresholds and communication needs. Reported LMX1A patients have used bilateral aids, including a child with reported improvement in speech perception. Benefit and timing require individual assessment.
Show evidence (2 references)
PMID:42253511 SUPPORT Human Clinical
"She was fitted with bilateral hearing aids, achieving near‐normal speech perception."
Amplification in a molecularly confirmed DFNA7 patient, with the outcome stated.
PMID:42253511 SUPPORT Human Clinical
"Individual II: 1 developed symmetric, bilateral severe SNHL across frequencies in early childhood and uses bilateral hearing aids."
A second aided individual in the same family, at the severe end of the range, which is what makes amplification the standing management rather than a single case.
Cochlear Implantation
Action: cochlear implantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cochlear implantation, annotated with Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Platform: Surgery
Cochlear implantation may be considered for severe-to-profound hearing loss with insufficient benefit from amplification. The reported LMX1A patient SB727 underwent unilateral implantation after left-ear deterioration and improved speech perception at three and six months. This one-patient experience cannot guarantee long-term outcome or preservation of every neural component in all carriers.
Show evidence (3 references)
PMID:36140227 SUPPORT Human Clinical
"The patient eventually underwent unilateral CI, with significant improvement in her speech perception scores 3 and 6 months postoperatively (Figure 2c)."
The implantation and its short-term speech outcome in a DFNA7 patient.
PMID:36140227 SUPPORT Human Clinical
"In one patient (SB727), hearing deteriorated to profound hearing loss in her left ear and the asymmetric hearing loss remained."
The clinical situation that led to implantation, and the reason it was unilateral: one ear reached profound loss while the asymmetry persisted.
PMID:36140227 SUPPORT Human Clinical
"Our results provide evidence for favorable CI outcomes in patients with LMX1A-related DFNA7."
The authors’ favorable summary rests on one LMX1A implant recipient with short follow-up.
Genetic Counselling with Audiologic Surveillance
Action: genetic counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is genetic counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Platform: Other
Counsel regarding dominant transmission, de novo occurrence and substantial variation in onset and severity. A mildly affected parent or a normal early hearing test cannot predict a child’s later course. Offer serial audiologic assessment and family testing for an established pathogenic variant.
Show evidence (3 references)
PMID:42253511 SUPPORT Human Clinical
"Clinical manifestations exhibited significant intrafamilial phenotypic variability, with hearing loss (HL) severity ranging from mild to profound, and onset varying from infancy to mid-adulthood."
The intrafamilial spread that makes prediction from a relative's course unsafe.
PMID:29754270 SUPPORT Human Clinical
"One variant, c.721G > C (p.Val241Leu), occurred de novo and is predicted to affect the homeodomain of LMX1A, which is essential for DNA binding."
De novo occurrence can account for an apparently isolated family presentation.
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT INDIRECT REVIEW SYNTHESIS Other
"Individuals with autosomal dominant hearing loss have a 50% chance of transmitting the pathogenic variant to each child."
General autosomal dominant transmission risk concerns inheriting the variant, not a guaranteed age or severity.
Communication support and hearing surveillance
Platform: Other
Provide age-appropriate communication and speech-language support, serial audiologic assessment, and counseling on excessive noise exposure. These measures derive from general hearing-loss guidance; lack of a DFNA7-specific trial is not a reason to omit communication support.
Show evidence (4 references)
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT INDIRECT REVIEW SYNTHESIS Other
"Habilitation for hearing loss includes improved access to sound through hearing aids or cochlear implants"
General GeneReviews hearing-loss management guidance, applied according to individual communication and audiologic needs.
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT INDIRECT REVIEW SYNTHESIS Other
"persons with documented hearing loss should be counseled appropriately and repeated overexposure to loud noises should be avoided"
General GeneReviews hearing-loss management guidance, applied according to individual communication and audiologic needs.
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT INDIRECT REVIEW SYNTHESIS Other
"Regular follow up is recommended for all individuals with genetic hearing loss"
General GeneReviews surveillance or individualized educational/communication guidance; this is not a DFNA7-specific trial.
+ 1 more reference
🔬

Diagnosis

2
Molecular diagnosis with clinical and vestibular assessment
Consider LMX1A within hearing-loss multigene panels or genomic testing for dominant sensorineural loss, whether symmetric or asymmetric. Interpret sequence variants using segregation, phenotype and variant-specific evidence; a VUS is not diagnostic. Audiology defines each ear’s severity and progression, and vestibular evaluation can identify deficits even without reported vertigo. Normal imaging is compatible with the diagnosis; bilateral cochlear-aperture stenosis was reported in one severely affected proband, with imaging unavailable for other affected relatives. This does not establish a universal malformation or proven structural mediator.
Show evidence (4 references)
PMID:35711095 SUPPORT Human Clinical
"For the first time, we suggest that LMX1A is one of the candidate genes which, if altered, could be associated with dominantly inherited asymmetric hearing loss."
The authors' explicit diagnostic recommendation.
PMID:42253511 SUPPORT Human Clinical
"High-resolution imaging revealed bilateral cochlear aperture stenosis (CAS) in the severely affected proband."
One proband had bilateral cochlear-aperture stenosis; its prevalence and relationship to the allele remain uncertain.
PMID:29754270 SUPPORT Human Clinical
"recommend screening for HI in subjects with mono-allelic loss of LMX1A."
The reverse direction of ascertainment, and the practically useful one: someone found to have lost one LMX1A copy for another reason, such as a chromosomal deletion, should have their hearing checked.
+ 1 more reference
📊

Prevalence

1
Published cases included in the April 2025 ClinGen curation
Cases In Literature
The ClinGen summary includes 12 variants in at least 26 probands across seven publications. This is a dated curation inventory, not a population prevalence or a count of variants with identical pathogenic certainty. Later reports add candidates and pedigrees.
Show evidence (1 reference)
CGGV:assertion_163f8708-7d3b-424a-826a-76e37260745c-2025-04-22T160000.000Z SUPPORT REVIEW SYNTHESIS Other
"12 variants (missense, nonsense, frameshift) that have been reported in at least 26 probands in 7 publications"
The external curation’s stated inventory; overlapping publications and variant-level classifications require separate interpretation.
📊

Related Datasets

1
A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7 geo:GSE299979
RNA sequencing of HEI-OC1 cells expressing wild-type or c.405delT Lmx1a. The paper presents three biological replicates per group.
mouse BULK RNA SEQ
PMID:42253511
Exploratory overexpression comparison; the GEO summary emphasizes neurodevelopmental/synaptic/mitochondrial pathways, whereas the final paper also emphasizes immune and ER-stress enrichment. Neither summary is patient-tissue evidence. No proteomics accession is asserted.
Show evidence (1 reference)
GEO:GSE299979 SUPPORT In Vitro
"RNA sequencing (RNA-seq) of HEI-OC1 cells"
Generated GEO record confirms the system and assay; the primary paper supplies the experimental interpretation.
🧫

Experimental Models

2
HEK293 LMX1A transactivation reporter CELL_LINE
Transient wild-type and mutant LMX1A expression with INS-promoter firefly luciferase and Renilla normalization. Five dominant variants reduced activity; recessive p.Ile369Thr retained wild-type-like activity. WT/mutant titration was performed for p.Phe135LeufsTer3.
Publication
PMID:42253511
Pathograph links
Reduced Transactivation of LMX1A Target Genes partially recapitulates fidelity: moderate Directly measures reporter transactivation in a nonauditory cell line.
Limitations: Overexpression and the INS promoter do not reconstruct native auditory dosage or downstream target selection.
Readouts
Normalized INS-promoter luciferase activity
Direction: DECREASED
Interpretation: Reduced for the five tested dominant alleles, not for recessive p.Ile369Thr.
Show evidence (1 reference)
PMID:42253511 SUPPORT In Vitro
"our functional assays demonstrated a profound loss of transactivation capacity for multiple LMX1A variants affecting the LIM domains and homeodomains"
Reporter result; the adjacent source sentence explicitly distinguishes the recessive allele.
Show evidence (1 reference)
PMID:42253511 SUPPORT In Vitro
"Each well received 0.1 μg pGL4.12‐INS‐luc, 0.1 μg either WT or mutant LMX1A expression plasmid"
HEK293 reporter uses an INS-promoter construct, not a defined native cochlear target.
Show evidence (1 reference)
PMID:42253511 SUPPORT In Vitro
"Each well received 0.1 μg pGL4.12‐INS‐luc, 0.1 μg either WT or mutant LMX1A expression plasmid"
HEK293 reporter uses an INS-promoter construct, not a defined native cochlear target.
HEI-OC1 Lmx1a overexpression and RNA-decay model CELL_LINE
Mouse auditory cell-line transfection with wild-type or c.405delT Lmx1a. RNA sequencing and exploratory DIA proteomics assess downstream signatures; Actinomycin D chase measures transfected RNA stability. This is not patient cochlear tissue or an endogenous heterozygous knock-in.
Publication
PMID:42253511
RNA-seq is deposited as GSE299979. The source warns that omics signatures may reflect nonspecific manipulation or overexpression stress; necroptosis enrichment is not a measured death mechanism.
Show evidence (1 reference)
PMID:42253511 SUPPORT In Vitro
"Actinomycin D (ActD) chase assays were performed in transfected HEI‐OC1 cells to evaluate mRNA stability."
Defines the transfected RNA-decay system.
🐁

Animal Models

3
Lmx1a mutanlallemand and Belly Spot and Deafness mice
Spontaneous functional-null alleles produce severe congenital cochleovestibular malformations and deafness in homozygotes. ABR comparisons include approximately six-week-old mice and sixteen-week-old complementation offspring. Whole-embryo E10.5 RNA for Hmx2/3 and Pax2 was reduced, but early otic Hmx3/Pax2 protein patterns were similar; the authors caution that RNA changes may arise outside the ear or secondarily to malformed structures. These are not demonstrated direct auditory transcriptional targets.
Species
Mouse
Genotype
Lmx1a mtl splice-site or bsd exon-3 deletion alleles; homozygotes, heterozygotes and controls
Genes
LMX1A hgnc:6653 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns LMX1A (hgnc:6653). hgnc:6653 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:23226461
Pathograph links
Cochleovestibular Dysfunction partially recapitulates fidelity: low Models loss of cochleovestibular function after biallelic disruption; does not reproduce the patient heterozygous genotype.
Limitations: The severe prenatal malformation and gene dosage differ from most human presentations. Normal young heterozygotes do not exclude later or allele-specific effects, and human disease is not exclusively postdevelopmental.
Readouts
ABR in homozygous mtl/bsd mutants
Direction: DECREASED
Interpretation: No evoked response at the maximum tested stimulus of 95 dB SPL.
Show evidence (1 reference)
PMID:23226461 SUPPORT Model Organism
"both mtl and bsd homozygotes showed no ABR response at 95 dB SPL"
Auditory evoked-response result, not a transcription-factor activity assay.
ABR thresholds in heterozygous controls
Direction: UNCHANGED
Interpretation: Normal thresholds at the tested young ages.
Show evidence (1 reference)
PMID:23226461 SUPPORT Model Organism
"The analysis of auditory brainstem responses (ABR) showed that mtl and bsd homozygotes are deaf, whereas heterozygous and wildtype littermates have normal hearing."
At tested young ages, homozygotes had no ABR up to the stimulus ceiling while heterozygotes had normal thresholds; this is an age- and allele-bounded comparison.
Show evidence (1 reference)
PMID:23226461 SUPPORT Model Organism
"The analysis of auditory brainstem responses (ABR) showed that mtl and bsd homozygotes are deaf, whereas heterozygous and wildtype littermates have normal hearing."
At tested young ages, homozygotes had no ABR up to the stimulus ceiling while heterozygotes had normal thresholds; this is an age- and allele-bounded comparison.
Show evidence (1 reference)
PMID:23226461 SUPPORT Model Organism
"The characterization of these two new Lmx1a alleles highlights the critical role of this gene in the development of the cochlea and vestibular system."
The authors' own summary of what these alleles establish.
Lmx1a drJ functional-null mouse
The drJ functional-null allele disrupts sensory/nonsensory boundaries and formation of the membranous labyrinth. Later work documents defective strial differentiation and endocochlear potential below 6 mV in homozygotes. The 2025 study explicitly measured wild-type, heterozygous and homozygous animals at P12 and P21, six per age/genotype. Loss of cochlear melanoblast labeling does not establish whether the cells died or changed location.
Species
Mouse
Genotype
Lmx1a drJ/drJ with heterozygous and wild-type controls
Genes
LMX1A hgnc:6653 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns LMX1A (hgnc:6653). hgnc:6653 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:19540218
Pathograph links
Impaired Strial Differentiation partially recapitulates fidelity: low Establishes the null-model strial phenotype underlying the candidate human mechanism.
Limitations: The strong phenotype is biallelic and developmental. Human heterozygous strial physiology and a late-life heterozygote time course are not established by this experiment.
Readouts
Strial differentiation markers
Direction: DECREASED
Interpretation: Loss of marginal/intermediate markers in the homozygous mutant.
Show evidence (1 reference)
PMID:40109362 SUPPORT INDIRECT Model Organism
"we observe a lack of proteins specific to the stria vascularis, such as BSND and KCNQ1 in marginal cells and CD44 in intermediate cells."
Strial differentiation-marker loss in the homozygous model.
Show evidence (1 reference)
PMID:40109362 SUPPORT INDIRECT Model Organism
"we observe a lack of proteins specific to the stria vascularis, such as BSND and KCNQ1 in marginal cells and CD44 in intermediate cells."
Strial differentiation-marker loss in the homozygous model.
Reduced Endocochlear Potential partially recapitulates fidelity: low Measures endocochlear-potential failure in the homozygous functional-null model.
Limitations: The strong phenotype is biallelic and developmental. Human heterozygous strial physiology and a late-life heterozygote time course are not established by this experiment.
Readouts
Homozygous endocochlear potential at P12 and P21
Direction: DECREASED
Interpretation: Below 6 mV; wild-type and heterozygous groups were measured in the same study.
Show evidence (2 references)
PMID:40109362 SUPPORT Model Organism
"We examined the functional status of the Lmx1a mutant stria by comparing wild-type, heterozygote, and mutant EP (endocochlear potential) at P12 and P21. Six animals from each age/genotype were used."
Directly establishes the heterozygous comparison that the previous entry incorrectly called absent.
+ 1 more reference
Show evidence (1 reference)
PMID:40109362 SUPPORT INDIRECT Model Organism
"we measured the EP at P12 (during development) and P21 (mature EP) and confirmed a total absence of EP remained at less than 6-mV"
The source calls EP absent but reports a residual measurement below 6 mV, not exact mathematical zero.
Show evidence (2 references)
PMID:19540218 SUPPORT Model Organism
"Furthermore, aberrant and ectopic sensory organs are observed; most striking among these is vestibular-like hair cells located in the cochlear duct."
The boundary-violation phenotype that establishes Lmx1a's selector-gene role, and the clearest illustration of how different the null is from the human disease.
PMID:40109362 SUPPORT Model Organism
"The transcription factor Lmx1a is widely expressed during early inner ear development, and mice lacking Lmx1a expression exhibit fusion of cochlear and vestibular hair cells and fail to form the ductus reuniens and the endolymphatic sac."
The developmental scope of Lmx1a loss in the null, summarised by the same group.
Lmx1a and Lmx1b central auditory allelic series
At P14, Lmx1a-null mice had reduced excitatory-neuron densities in dorsal/ventral cochlear nuclei, aggravated by loss of one Lmx1b copy; double heterozygotes were normal for those measures. Roof-plate Bmp6 expression and Atoh1-positive progenitors were reduced at embryonic stages. P0/P14 apoptosis staining did not increase, without excluding other ages. Central projection defects could also reflect inner-ear abnormalities; tissue-specific conditional studies were proposed rather than performed.
Species
Mouse
Genotype
Lmx1a drJ functional null with Lmx1b null alleles; Lmx1a-/-, Lmx1a-/-;Lmx1b+/-, double heterozygotes and controls
Genes
LMX1A hgnc:6653 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns LMX1A (hgnc:6653). hgnc:6653 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:41991696
Pathograph links
Cochleovestibular Dysfunction partially recapitulates fidelity: low Demonstrates an additional central developmental requirement for Lmx1a, with partial Lmx1b redundancy.
Limitations: Biallelic disruption differs from DFNA7, and normal double-heterozygous counts argue against simply equating these findings with human haploinsufficiency. No patient central lesion is established.
Readouts
Excitatory-neuron density in cochlear nuclei
Direction: DECREASED
Interpretation: Reduced in Lmx1a-null mice and further reduced with an additional lost Lmx1b copy.
Show evidence (1 reference)
PMID:41991696 SUPPORT INDIRECT Model Organism
"Loss of Lmx1a reduced distinct populations of excitatory neurons in dorsal (DCN) and ventral (VCN) cochlear nuclei and their innervation from the inner ear."
Central auditory phenotype in the Lmx1a-null allelic series; not demonstrated in human heterozygotes.
Show evidence (1 reference)
PMID:41991696 SUPPORT INDIRECT Model Organism
"Loss of Lmx1a reduced distinct populations of excitatory neurons in dorsal (DCN) and ventral (VCN) cochlear nuclei and their innervation from the inner ear."
Central auditory phenotype in the Lmx1a-null allelic series; not demonstrated in human heterozygotes.
Show evidence (1 reference)
PMID:41991696 SUPPORT INDIRECT Model Organism
"Loss of Lmx1a reduced distinct populations of excitatory neurons in dorsal (DCN) and ventral (VCN) cochlear nuclei and their innervation from the inner ear."
Central auditory phenotype in the Lmx1a-null allelic series; not demonstrated in human heterozygotes.
{ }

Source YAML

click to show 
name: Autosomal Dominant Nonsyndromic Hearing Loss 7
category: Mendelian
creation_date: '2026-08-28T00:00:00Z'
synonyms:
- DFNA7
- autosomal dominant nonsyndromic deafness 7
- autosomal dominant nonsyndromic deafness type 7
- autosomal dominant deafness 7
- deafness, autosomal dominant 7
- LMX1A-related autosomal dominant nonsyndromic hearing loss
description: DFNA7 is LMX1A-related autosomal dominant nonsyndromic sensorineural hearing loss, sometimes accompanied by vestibular dysfunction. Onset ranges from congenital to adult, severity from mild to profound, and hearing can be symmetric or asymmetric within the same family. Progressive loss is documented, but neither normal newborn hearing nor universally normal inner-ear imaging should be assumed. Haploinsufficiency is the favored molecular explanation for studied dominant alleles, supported by reduced reporter transactivation and allele-specific functional work. The relevant cochlear targets, affected cell populations and balance between developmental defects and postdevelopmental dysfunction remain unresolved. Homozygous functional-null mice establish developmental roles in the inner ear and central auditory system; they do not reproduce the endogenous heterozygous patient genotype. A separately reported recessive LMX1A phenotype is discussed as an allelic boundary, not a second inheritance mode of this dominant entry.
disease_term:
  preferred_term: autosomal dominant nonsyndromic hearing loss 7
  term:
    id: MONDO:0011074
    label: autosomal dominant nonsyndromic hearing loss 7
parents:
- Autosomal Dominant Nonsyndromic Hearing Loss
inheritance:
- name: Autosomal dominant
  description: Heterozygous pathogenic LMX1A variants segregate through multiple generations; de novo variants also occur. Expressivity varies substantially within families. A heterozygous parent can transmit the variant to half of offspring, but this does not predict age at onset or severity.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here, we identified heterozygous pathogenic missense variants of LMX1A in two families of Dutch origin with progressive nonsyndromic hearing impairment (HI), using whole exome sequencing.
    explanation: The founding dominant families and the heterozygous state of the alleles.
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: One variant, c.721G > C (p.Val241Leu), occurred de novo and is predicted to affect the homeodomain of LMX1A, which is essential for DNA binding.
    explanation: The authors inferred de novo p.Val241Leu in subject II:7 from haplotypes shared with noncarrier siblings; this is distinct from direct testing of both parents.
  - reference: PMID:36519758
    reference_title: 'A novel frameshift variant of LMX1A that leads to autosomal dominant non-syndromic sensorineural hearing loss: functional characterization of the C-terminal domain in LMX1A.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This C-terminal frameshift mutation co-segregated with autosomal dominant (AD) NSHL in a four-generation Chinese family
    explanation: Four-generation cosegregation of a truncating allele with dominant disease.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    snippet: Individuals with autosomal dominant hearing loss have a 50% chance of transmitting the pathogenic variant to each child.
    explanation: General autosomal dominant transmission risk concerns inheriting the variant, not a guaranteed age or severity.
    evidence_source: OTHER
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
pathophysiology:
- name: LMX1A Haploinsufficiency
  description: Dominant disease alleles reduce functional LMX1A activity through heterogeneous lesions, including impaired DNA binding, truncation and, for p.Phe135LeufsTer3, faster decay of transfected mutant RNA. Functional insufficiency does not mean every missense variant lowers protein abundance. Reporter titration favors haploinsufficiency for the tested alleles but does not exclude every alternative effect in native cochlear cells. The 2026 Actinomycin D assay measures RNA stability in transfected HEI-OC1 cells; the authors interpret this as nonsense-mediated decay, without directly testing the surveillance pathway in patient cochlear tissue. No augmentation treatment is established by these experiments.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: LMX1A
    term:
      id: hgnc:6653
      label: LMX1A
  downstream:
  - target: Reduced Transactivation of LMX1A Target Genes
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Furthermore, plasmid titration experiments and Actinomycin D chase assays functionally corroborated the haploinsufficiency mechanism and excluded the dominant-negative effect.
    explanation: The authors’ mechanistic interpretation of plasmid titration and RNA-decay assays for p.Phe135LeufsTer3; conclusions are bounded by the transfected cell systems and tested allele.
  - reference: PMID:32840933
    reference_title: Novel genotype-phenotype correlation of functionally characterized LMX1A variants linked to sensorineural hearing loss.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Further, our dominant LMX1A variant exerted pathogenic effects via haploinsufficiency rather than dominant-negative effect.
    explanation: Functional study of p.Arg199Gly favored haploinsufficiency; this does not establish identical behavior for every allele.
  - reference: PMID:35254497
    reference_title: Update on CD164 and LMX1A genes to strengthen their causative role in autosomal dominant hearing loss.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We also provide further evidence for haploinsufficiency as the pathogenic mechanism underlying LMX1A-related ADHL.
    explanation: Additional functional evidence for p.Ala229Asp; overlapping investigators and similar reporter approaches do not constitute three fully independent model systems.
  genetic_context:
    genes:
    - preferred_term: LMX1A
      term:
        id: hgnc:6653
        label: LMX1A
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    functional_impact_category: LOSS_OF_FUNCTION
    notes: Functional insufficiency is favored for studied pathogenic dominant alleles; reported VUSs and the recessive p.Ile369Thr allele require separate interpretation.
- name: Reduced Transactivation of LMX1A Target Genes
  description: Several dominant LMX1A variants reduce reporter transactivation. The 2026 HEK293 assay used an INS-promoter luciferase construct and found reduced activity for five dominant variants, whereas recessive p.Ile369Thr retained wild-type-like activity. These assays do not identify native auditory targets. Homeodomain and C-terminal changes can impair protein–DNA interaction; a structural study of WNT1/PITX3 promoter recognition and neuronal cells supplies additional noncochlear evidence. A proposed activity–severity correlation from a small allele comparison is not a validated predictor of individual prognosis, especially given wide intrafamilial variability.
  biological_scale: MOLECULAR
  molecular_functions:
  - preferred_term: DNA-binding transcription factor activity
    term:
      id: GO:0003700
      label: DNA-binding transcription factor activity
    modifier: DECREASED
  downstream:
  - target: Cochleovestibular Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: The intervening auditory transcriptional program and affected cell populations are incompletely resolved.
  evidence:
  - reference: PMID:35711095
    reference_title: 'Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Compared with the wild-type protein, all mutant LMX1A proteins had significantly reduced transactivation efficiency, indicating that the ability to elicit transcription of the downstream target genes of LMX1A was severely compromised.
    explanation: Reduced transactivation in the tested variants, including p.Gln240Arg, which remained a VUS in that publication; an assay effect alone does not establish pathogenicity.
  - reference: PMID:32840933
    reference_title: Novel genotype-phenotype correlation of functionally characterized LMX1A variants linked to sensorineural hearing loss.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Resultantly, p.Arg199Gly manifesting the most severe NSHL showed the biggest reduction of transcriptional activity in contrast with moderately reduced activity of p.Cys97Ser and p.Val241Leu associated with less severe progressive NSHL, proposing a genotype-phenotype correlation.
    explanation: A proposed correlation across a small allele comparison; clinical severity is not a calibrated dose-response and varies within families.
  - reference: PMID:35254497
    reference_title: Update on CD164 and LMX1A genes to strengthen their causative role in autosomal dominant hearing loss.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: and one family with a novel variant in LMX1A (c.686C>A; p.(Ala229Asp)) that impairs its transcriptional activity
    explanation: A further allele independently shown to impair transcriptional activity.
  - reference: PMID:36519758
    reference_title: 'A novel frameshift variant of LMX1A that leads to autosomal dominant non-syndromic sensorineural hearing loss: functional characterization of the C-terminal domain in LMX1A.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: In addition, electrophoresis mobility shift assay and luciferase assays have shown that the highly conserved C-terminal domain (amino acid 306-382) of the LMX1A was required for regulating the protein-DNA interaction and transactivation in vitro.
    explanation: The assay supports a C-terminal contribution to DNA interaction and transactivation; it does not make every distal variant pathogenic.
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Luciferase reporter assays showing reduced transactivation by LMX1A mutants relative to WT, p.Ile369Thr retains WT‐like activity.
    explanation: Figure 6 distinguishes the recessive allele from the tested dominant variants in this reporter assay.
  - reference: PMID:38465368
    reference_title: Structural insights into the recognition of the A/T-rich motif in target gene promoters by the LMX1a homeobox domain.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: the LMX1a homeobox domain employed its α3 helix and an N-terminal loop to achieve specific target recognition.
    explanation: Crystal structures concern WNT1/PITX3 promoter DNA. Their relevance to hearing alleles is mechanistic support, not identification of the cochlear regulon.
    directness: INDIRECT
- name: Impaired Strial Differentiation
  biological_scale: TISSUE
  mechanism_confidence: HYPOTHETICAL
  description: Homozygous Lmx1a functional-null mice fail to establish normal marginal/intermediate strial layers. This demonstrates a developmental strial requirement in that model. A corresponding differentiation defect in human heterozygotes is hypothetical. Disappearance of cochlear melanoblast labeling was observed, but cell death versus altered recruitment or migration was not resolved by lineage tracing.
  evidence:
  - reference: PMID:40109362
    reference_title: Lmx1a is essential for marginal cell differentiation and stria vascularis formation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: we observe a lack of proteins specific to the stria vascularis, such as BSND and KCNQ1 in marginal cells and CD44 in intermediate cells.
    explanation: Strial differentiation-marker loss in the homozygous model.
    directness: INDIRECT
  downstream:
  - target: Reduced Endocochlear Potential
    causal_link_type: DIRECT
    description: Defective strial formation accompanies failure to establish the normal endocochlear potential in the homozygous mouse; the human branch remains hypothetical.
- name: Reduced Endocochlear Potential
  biological_scale: TISSUE
  mechanism_confidence: HYPOTHETICAL
  description: Homozygous functional-null mice have endocochlear potentials below 6 mV at P12 and P21. Whether subtler strial physiology mediates dominant human hearing loss remains hypothetical. The 2025 experiment includes wild-type, heterozygous and homozygous animals, so absence of heterozygote measurements cannot be claimed.
  evidence:
  - reference: PMID:40109362
    reference_title: Lmx1a is essential for marginal cell differentiation and stria vascularis formation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: we measured the EP at P12 (during development) and P21 (mature EP) and confirmed a total absence of EP remained at less than 6-mV
    explanation: The source calls EP absent but reports a residual measurement below 6 mV, not exact mathematical zero.
    directness: INDIRECT
  downstream:
  - target: Cochleovestibular Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: The null-model physiology suggests a candidate auditory mechanism; mediation in human heterozygotes is untested.
- name: Cochleovestibular Dysfunction
  description: Heterozygous LMX1A disease can impair cochlear and vestibular function through pathways that remain incompletely resolved. An ongoing maintenance requirement and subtle developmental defects are plausible and may coexist. Congenital cases and cochlear-aperture stenosis in one 2026 proband prevent a universal postdevelopmental-only model. Lmx1a expression becomes restricted to nonsensory epithelia during ear development, so a mature hair-cell-autonomous transcriptional defect should not be assumed. Clinical imaging and progression alone do not distinguish the alternatives.
  biological_scale: TISSUE
  downstream:
  - target: Progressive Sensorineural Hearing Impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Vestibular Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Congenital Severe-to-Profound Sensorineural Hearing Impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Postlingual Sensorineural Hearing Impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Asymmetric Sensorineural Hearing Loss
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Downsloping High-Frequency Audiogram Configuration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We propose that a single LMX1A wild-type copy is sufficient for normal development but insufficient for maintenance of cochleovestibular function.
    explanation: The original authors’ maintenance hypothesis, not a demonstrated universal sequence.
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The late-onset progressive phenotype and the absence of cochleovestibular malformations on computed tomography scans indicate that heterozygous defects of LMX1A do not result in severe developmental abnormalities in humans.
    explanation: Normal labyrinth imaging in the examined founding-family subjects; other relatives and subsequent congenital presentations prevent generalization to all patients.
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Alternatively, minor cochleovestibular developmental abnormalities could eventually lead to the progressive phenotype seen in the families.
    explanation: The authors explicitly retain a subtle developmental alternative; postdevelopmental maintenance was not established.
  - reference: PMID:19540218
    reference_title: Lmx1a maintains proper neurogenic, sensory, and non-sensory domains in the mammalian inner ear.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: its expression is soon restricted to the non-sensory regions of the developing ear.
    explanation: Mouse expression limits the inference of a mature hair-cell-autonomous lesion.
    directness: INDIRECT
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: High-resolution imaging revealed bilateral cochlear aperture stenosis (CAS) in the severely affected proband.
    explanation: One proband had a structural finding; other affected relatives lacked imaging, so penetrance and causal mediation are unresolved.
  mechanism_confidence: PROVISIONAL
phenotypes:
- name: Progressive Sensorineural Hearing Impairment
  category: Auditory
  description: Progressive bilateral sensorineural hearing loss is documented in several pedigrees. Congenital presentation also occurs, and short follow-up may not demonstrate progression in every individual.
  phenotype_term:
    preferred_term: Progressive sensorineural hearing impairment
    term:
      id: HP:0000408
      label: Progressive sensorineural hearing impairment
  evidence:
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here, we identified heterozygous pathogenic missense variants of LMX1A in two families of Dutch origin with progressive nonsyndromic hearing impairment (HI), using whole exome sequencing.
    explanation: Progressive nonsyndromic hearing impairment in the founding families.
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: cosegregating with progressive and asymmetric sensorineural hearing loss
    explanation: The 2026 family is described as progressive, but the paper explicitly lacks longitudinal audiograms; observed longitudinal progression is supported by other pedigrees.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    snippet: In general, autosomal dominant nonsyndromic hearing loss is postlingual, progressive, and high frequency.
    explanation: General dominant nonsyndromic hearing-loss pattern; DFNA7 also includes congenital, symmetric and atypical presentations.
    evidence_source: OTHER
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Asymmetric Sensorineural Hearing Loss
  category: Auditory
  description: Hearing thresholds differ appreciably between the two ears. This was found in all probands and most affected individuals of a five-family DFNA7 series, and is unusual enough for a dominant nonsyndromic form that the authors proposed LMX1A as a candidate gene to consider specifically when asymmetric dominant hearing loss is encountered.
  phenotype_term:
    preferred_term: Asymmetric sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:35711095
    reference_title: 'Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It is important to note that asymmetric hearing loss was identified in all probands and most affected individuals, although the extent of asymmetry varied.
    explanation: The primary observation, with its own caveat about varying extent.
  - reference: PMID:35711095
    reference_title: 'Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: For the first time, we suggest that LMX1A is one of the candidate genes which, if altered, could be associated with dominantly inherited asymmetric hearing loss.
    explanation: The diagnostic implication the authors draw.
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: cosegregating with progressive and asymmetric sensorineural hearing loss
    explanation: Independent replication of asymmetry in a Chinese family.
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Subject IV:2 of family W15-0551 and subject II:2 of family 63136 displayed asymmetric HI, whereas the other affected individuals demonstrated symmetric HI.
    explanation: The founding families included both symmetric and asymmetric hearing loss.
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Individual I: 2 developed progressive, symmetric high‐frequency SNHL in his early 30s.'
    explanation: A symmetric carrier within the 2026 family demonstrates variable expression.
  - reference: PMID:36140227
    reference_title: 'Genetic Load of Alternations of Transcription Factor Genes in Non-Syndromic Deafness and the Associated Clinical Phenotypes: Experience from Two Tertiary Referral Centers.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Asymmetric hearing loss (interaural difference > 15dB) was identified in five of the nine patients.
    explanation: Five of nine LMX1A patients in this series; its methods/results thresholds differ, and the cohort overlaps prior Korean reports.
  - reference: PMID:36140227
    reference_title: 'Genetic Load of Alternations of Transcription Factor Genes in Non-Syndromic Deafness and the Associated Clinical Phenotypes: Experience from Two Tertiary Referral Centers.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Indeed, most LMX1A-related DFNA7 patients display audiologic asymmetry to varying degrees and a gradual progression of hearing loss.
    explanation: The qualitative claim alongside the count, and the phrase that matters is "to varying degrees" - asymmetry in DFNA7 is a spectrum measured against a threshold, not a categorical feature.
  notes: 'Asymmetry is represented using the sensorineural hearing-impairment term with the interaural pattern specified in prose. Frequencies differ across small, partially overlapping cohorts: two of seven founding-family subjects were asymmetric, and a later Korean series reported five of nine. That paper uses >10 dB in methods and >15 dB in results. A uniform population frequency or universal asymmetry is therefore not asserted.'
- name: Downsloping High-Frequency Audiogram Configuration
  category: Auditory
  description: Downsloping, high-frequency-predominant hearing loss occurs in the founding families and later reports, but configuration and severity vary and are not specific to LMX1A.
  phenotype_term:
    preferred_term: High-frequency sensorineural hearing impairment
    term:
      id: HP:0001757
      label: High-frequency sensorineural hearing impairment
  evidence:
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Affected subjects had mild to profound HI with overall a downsloping audiogram configuration
    explanation: The audiogram configuration across the founding families, with its severity range.
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Individual II: 2 exhibited high‐frequency SNHL with no documented history of exposure to known ototoxic agents.'
    explanation: High-frequency loss in an independent family, with ototoxic exposure explicitly excluded, which matters because the same audiogram shape is the signature of acquired causes.
- name: Vestibular Dysfunction
  category: Vestibular
  description: Vestibular involvement is variable. Four of seven affected individuals in the 2018 families reported episodic vertigo, sometimes with tinnitus. Formal vestibular testing was performed in three subjects and showed hypo/areflexia; two tested by cVEMP lacked responses. One subject with bilateral areflexia reported no vestibular complaints. These selected observations do not establish that half of all DFNA7 patients have objectively measured dysfunction.
  phenotype_term:
    preferred_term: Abnormal vestibular function
    term:
      id: HP:0001751
      label: Abnormal vestibular function
  evidence:
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: About half of the affected individuals displayed vestibular dysfunction and experienced symptoms thereof.
    explanation: The abstract summarizes vestibular involvement loosely; the full text distinguishes symptoms in four subjects from testing in three, including an asymptomatic subject.
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: cVEMPs showed no responses up to 100 dBnHL in both subjects, indicating dysfunction of the saccule.
    explanation: Localises the deficit to the saccule rather than leaving it at organ level, which is the kind of detail that distinguishes a measured vestibular phenotype from a reported symptom.
- name: Congenital Severe-to-Profound Sensorineural Hearing Impairment
  category: Auditory
  severity: SEVERE
  description: Congenital severe-to-profound hearing loss occurs with several dominant alleles. The p.Arg199Gly case had the largest reporter deficit in a small comparison, but congenital severity is not confined to that allele.
  phenotype_term:
    preferred_term: Congenital sensorineural hearing impairment
    term:
      id: HP:0008527
      label: Congenital sensorineural hearing impairment
  evidence:
  - reference: PMID:32840933
    reference_title: Novel genotype-phenotype correlation of functionally characterized LMX1A variants linked to sensorineural hearing loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: identification of a de novo, heterozygous, missense variant (c.595A > G; p.Arg199Gly) located in the homeodomain of LMX1A in a subject with congenital severe-to-profound deafness through Exome sequencing
    explanation: The congenital severe-to-profound case and the allele responsible.
  - reference: PMID:36519758
    reference_title: 'A novel frameshift variant of LMX1A that leads to autosomal dominant non-syndromic sensorineural hearing loss: functional characterization of the C-terminal domain in LMX1A.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In this family, the affected individuals exhibited the variable auditory phenotypes ranging from profound congenital deafness at birth or to mild/moderate HL in adulthood.
    explanation: Congenital profound deafness at one end of a single family's range, which is also the clearest statement of how wide intrafamilial variability is.
- name: Postlingual Sensorineural Hearing Impairment
  category: Auditory
  description: Other carriers develop recognized hearing loss after language acquisition, including in adulthood. This is one presentation within the broader congenital-to-adult spectrum.
  phenotype_term:
    preferred_term: Postlingual sensorineural hearing impairment
    term:
      id: HP:0008596
      label: Postlingual sensorineural hearing impairment
  evidence:
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinical manifestations exhibited significant intrafamilial phenotypic variability, with hearing loss (HL) severity ranging from mild to profound, and onset varying from infancy to mid-adulthood.
    explanation: Documents onset extending to mid-adulthood, and the intrafamilial spread that makes prognosis from an affected relative unreliable.
prevalence:
- population: Published cases included in the April 2025 ClinGen curation
  measure_type: CASES_IN_LITERATURE
  notes: The ClinGen summary includes 12 variants in at least 26 probands across seven publications. This is a dated curation inventory, not a population prevalence or a count of variants with identical pathogenic certainty. Later reports add candidates and pedigrees.
  evidence:
  - reference: CGGV:assertion_163f8708-7d3b-424a-826a-76e37260745c-2025-04-22T160000.000Z
    reference_title: LMX1A / autosomal dominant nonsyndromic hearing loss (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: 12 variants (missense, nonsense, frameshift) that have been reported in at least 26 probands in 7 publications
    explanation: The external curation’s stated inventory; overlapping publications and variant-level classifications require separate interpretation.
    quote_role: REVIEW_SYNTHESIS
genetic:
- name: LMX1A
  notes: 'LMX1A encodes a LIM-homeodomain transcription factor. Pathogenic dominant variants affect LIM, homeodomain and C-terminal regions. The 2026 c.405delT report uses NM_177398.4 and predicts p.Phe135LeufsTer3. Variant-specific classifications matter: p.Gln240Arg remained a VUS in the 2022 report and p.Val241Ala was reported as a VUS in the 2026 father–son report. Multiple substitutions at Val241 do not by themselves establish a mutational hotspot. The recessive p.Ile369Thr family is an allelic boundary, not evidence for recessive inheritance of DFNA7.'
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: LMX1A
    term:
      id: hgnc:6653
      label: LMX1A
  case_fractions:
  - population: Korean hearing loss probands undergoing exome sequencing
    case_fraction_percent: 0.7
    cohort_size: 728
    notes: Five LMX1A-associated families among 728 probands sequenced regardless of audiological phenotype, approximately 0.7%. This is a referral-cohort attribution rate, not population prevalence; the paper includes a VUS among its variants. Later Korean cohorts overlap and must not be pooled as independent families.
    evidence:
    - reference: PMID:35711095
      reference_title: 'Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Five LMX1A -associated DFNA7 families (approximately 0.7%), the pedigrees of whom indicated autosomal-dominant hearing loss, were identified, and segregation was studied using Sanger sequencing.
      explanation: The yield figure and its denominator.
    - reference: PMID:35711095
      reference_title: 'Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Among 728 probands of which genomic DNA went through exome sequencing regardless of any specific audiologic phenotypes, probands for which exome sequencing was performed and a causative LMX1A variant was found were all included.
      explanation: 'The ascertainment, which matters for interpreting the fraction: probands were sequenced regardless of audiological phenotype, so the denominator is not enriched for the asymmetric presentation LMX1A causes.'
  evidence:
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Pathogenic variants in the LIM-homeodomain transcription factor LMX1A represent a rare yet critical etiology for autosomal dominant nonsyndromic hearing loss 7 (DFNA7) and less frequently, its autosomal recessive counterpart (ARNSHL).
    explanation: The gene-disease relationship, and the existence of a recessive counterpart.
  - reference: CGGV:assertion_163f8708-7d3b-424a-826a-76e37260745c-2025-04-22T160000.000Z
    reference_title: LMX1A / autosomal dominant nonsyndromic hearing loss (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: there is definitive evidence supporting the relationship between LMX1A and autosomal dominant nonsyndromic deafness.
    explanation: ClinGen Hearing Loss GCEP classification approved at the 16 April 2025 meeting and recorded 22 April 2025; this concerns the dominant gene–disease relationship.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:41078281
    reference_title: A Novel Missense Variant in LMX1A Leads to Autosomal Dominant Nonsyndromic Hearing Loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Genetic testing revealed a variant of uncertain significance (p.Val241Ala) in LMX1A
    explanation: Candidate allele observed in affected father and son; preserve the reported uncertainty.
  - reference: PMID:35711095
    reference_title: 'Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: as a "variant of uncertain significance'' (p.Gln240Arg).
    explanation: The reporter-impaired p.Gln240Arg allele remained a VUS in this publication.
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: shared by the proband and her father. Sanger sequencing confirmed cosegregation of this variant with the auditory phenotype in all available affected family members
    explanation: Segregation of the novel c.405delT allele in the 2026 pedigree.
diagnosis:
- name: Molecular diagnosis with clinical and vestibular assessment
  description: Consider LMX1A within hearing-loss multigene panels or genomic testing for dominant sensorineural loss, whether symmetric or asymmetric. Interpret sequence variants using segregation, phenotype and variant-specific evidence; a VUS is not diagnostic. Audiology defines each ear’s severity and progression, and vestibular evaluation can identify deficits even without reported vertigo. Normal imaging is compatible with the diagnosis; bilateral cochlear-aperture stenosis was reported in one severely affected proband, with imaging unavailable for other affected relatives. This does not establish a universal malformation or proven structural mediator.
  evidence:
  - reference: PMID:35711095
    reference_title: 'Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: For the first time, we suggest that LMX1A is one of the candidate genes which, if altered, could be associated with dominantly inherited asymmetric hearing loss.
    explanation: The authors' explicit diagnostic recommendation.
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: High-resolution imaging revealed bilateral cochlear aperture stenosis (CAS) in the severely affected proband.
    explanation: One proband had bilateral cochlear-aperture stenosis; its prevalence and relationship to the allele remain uncertain.
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: recommend screening for HI in subjects with mono-allelic loss of LMX1A.
    explanation: 'The reverse direction of ascertainment, and the practically useful one: someone found to have lost one LMX1A copy for another reason, such as a chromosomal deletion, should have their hearing checked.'
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    snippet: The identification of variant(s) of uncertain significance cannot be used to confirm or rule out the diagnosis.
    explanation: General genetic-hearing-loss guidance on VUS interpretation.
    evidence_source: OTHER
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Distinguish recessive LMX1A-related hearing loss
  description: A homozygous p.Ile369Thr variant was reported in a consanguineous Pakistani family with severe-to-profound hearing loss. Its predicted structural interactions do not establish the same mechanism as dominant alleles. In the 2026 INS-promoter assay it retained wild-type-like activity. Evaluate zygosity, segregation and the clinical context separately.
  evidence:
  - reference: PMID:29971487
    reference_title: A variant in LMX1A causes autosomal recessive severe-to-profound hearing impairment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This led to the identification of a missense variant (p.Ile369Thr) in the LMX1A gene affecting a conserved residue in the C-terminus of the protein
    explanation: The separate recessive pedigree defines an allelic boundary.
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Luciferase reporter assays showing reduced transactivation by LMX1A mutants relative to WT, p.Ile369Thr retains WT‐like activity.
    explanation: Figure 6 distinguishes the recessive allele from the tested dominant variants in this reporter assay.
treatments:
- name: Hearing Amplification
  description: Fit and adjust hearing aids according to ear-specific thresholds and communication needs. Reported LMX1A patients have used bilateral aids, including a child with reported improvement in speech perception. Benefit and timing require individual assessment.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: hearing aid fitting
  evidence:
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: She was fitted with bilateral hearing aids, achieving near‐normal speech perception.
    explanation: Amplification in a molecularly confirmed DFNA7 patient, with the outcome stated.
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Individual II: 1 developed symmetric, bilateral severe SNHL across frequencies in early childhood and uses bilateral hearing aids.'
    explanation: A second aided individual in the same family, at the severe end of the range, which is what makes amplification the standing management rather than a single case.
- name: Cochlear Implantation
  description: Cochlear implantation may be considered for severe-to-profound hearing loss with insufficient benefit from amplification. The reported LMX1A patient SB727 underwent unilateral implantation after left-ear deterioration and improved speech perception at three and six months. This one-patient experience cannot guarantee long-term outcome or preservation of every neural component in all carriers.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: cochlear implantation
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:36140227
    reference_title: 'Genetic Load of Alternations of Transcription Factor Genes in Non-Syndromic Deafness and the Associated Clinical Phenotypes: Experience from Two Tertiary Referral Centers.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The patient eventually underwent unilateral CI, with significant improvement in her speech perception scores 3 and 6 months postoperatively (Figure 2c).
    explanation: The implantation and its short-term speech outcome in a DFNA7 patient.
  - reference: PMID:36140227
    reference_title: 'Genetic Load of Alternations of Transcription Factor Genes in Non-Syndromic Deafness and the Associated Clinical Phenotypes: Experience from Two Tertiary Referral Centers.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In one patient (SB727), hearing deteriorated to profound hearing loss in her left ear and the asymmetric hearing loss remained.
    explanation: 'The clinical situation that led to implantation, and the reason it was unilateral: one ear reached profound loss while the asymmetry persisted.'
  - reference: PMID:36140227
    reference_title: 'Genetic Load of Alternations of Transcription Factor Genes in Non-Syndromic Deafness and the Associated Clinical Phenotypes: Experience from Two Tertiary Referral Centers.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our results provide evidence for favorable CI outcomes in patients with LMX1A-related DFNA7.
    explanation: The authors’ favorable summary rests on one LMX1A implant recipient with short follow-up.
  notes: Implantation is the surgical intervention using a cochlear implant device. Only SB727 contributes LMX1A implantation outcomes in the cited multi-gene study; its POU4F3 and EYA4 outcomes are not attributed to DFNA7.
- name: Genetic Counselling with Audiologic Surveillance
  description: Counsel regarding dominant transmission, de novo occurrence and substantial variation in onset and severity. A mildly affected parent or a normal early hearing test cannot predict a child’s later course. Offer serial audiologic assessment and family testing for an established pathogenic variant.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinical manifestations exhibited significant intrafamilial phenotypic variability, with hearing loss (HL) severity ranging from mild to profound, and onset varying from infancy to mid-adulthood.
    explanation: The intrafamilial spread that makes prediction from a relative's course unsafe.
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: One variant, c.721G > C (p.Val241Leu), occurred de novo and is predicted to affect the homeodomain of LMX1A, which is essential for DNA binding.
    explanation: De novo occurrence can account for an apparently isolated family presentation.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    snippet: Individuals with autosomal dominant hearing loss have a 50% chance of transmitting the pathogenic variant to each child.
    explanation: General autosomal dominant transmission risk concerns inheriting the variant, not a guaranteed age or severity.
    evidence_source: OTHER
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Communication support and hearing surveillance
  description: Provide age-appropriate communication and speech-language support, serial audiologic assessment, and counseling on excessive noise exposure. These measures derive from general hearing-loss guidance; lack of a DFNA7-specific trial is not a reason to omit communication support.
  therapeutic_modality: OTHER
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    snippet: Habilitation for hearing loss includes improved access to sound through hearing aids or cochlear implants
    explanation: General GeneReviews hearing-loss management guidance, applied according to individual communication and audiologic needs.
    evidence_source: OTHER
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    snippet: persons with documented hearing loss should be counseled appropriately and repeated overexposure to loud noises should be avoided
    explanation: General GeneReviews hearing-loss management guidance, applied according to individual communication and audiologic needs.
    evidence_source: OTHER
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    snippet: Regular follow up is recommended for all individuals with genetic hearing loss
    explanation: General GeneReviews surveillance or individualized educational/communication guidance; this is not a DFNA7-specific trial.
    evidence_source: OTHER
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    snippet: Physical, occupational, and speech-language therapy services will be provided in the IEP to the extent that the need affects the child's access to academic material.
    explanation: General GeneReviews surveillance or individualized educational/communication guidance; this is not a DFNA7-specific trial.
    evidence_source: OTHER
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
animal_models:
- name: Lmx1a mutanlallemand and Belly Spot and Deafness mice
  species: Mouse
  genotype: Lmx1a mtl splice-site or bsd exon-3 deletion alleles; homozygotes, heterozygotes and controls
  publication: PMID:23226461
  description: Spontaneous functional-null alleles produce severe congenital cochleovestibular malformations and deafness in homozygotes. ABR comparisons include approximately six-week-old mice and sixteen-week-old complementation offspring. Whole-embryo E10.5 RNA for Hmx2/3 and Pax2 was reduced, but early otic Hmx3/Pax2 protein patterns were similar; the authors caution that RNA changes may arise outside the ear or secondarily to malformed structures. These are not demonstrated direct auditory transcriptional targets.
  genes:
  - preferred_term: LMX1A
    term:
      id: hgnc:6653
      label: LMX1A
  modeled_mechanisms:
  - target: Cochleovestibular Dysfunction
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: Models loss of cochleovestibular function after biallelic disruption; does not reproduce the patient heterozygous genotype.
    limitations: The severe prenatal malformation and gene dosage differ from most human presentations. Normal young heterozygotes do not exclude later or allele-specific effects, and human disease is not exclusively postdevelopmental.
    evidence:
    - reference: PMID:23226461
      reference_title: Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: The analysis of auditory brainstem responses (ABR) showed that mtl and bsd homozygotes are deaf, whereas heterozygous and wildtype littermates have normal hearing.
      explanation: At tested young ages, homozygotes had no ABR up to the stimulus ceiling while heterozygotes had normal thresholds; this is an age- and allele-bounded comparison.
    readouts:
    - name: ABR in homozygous mtl/bsd mutants
      target: Cochleovestibular Dysfunction
      direction: DECREASED
      interpretation: No evoked response at the maximum tested stimulus of 95 dB SPL.
      evidence:
      - reference: PMID:23226461
        reference_title: Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: both mtl and bsd homozygotes showed no ABR response at 95 dB SPL
        explanation: Auditory evoked-response result, not a transcription-factor activity assay.
    - name: ABR thresholds in heterozygous controls
      target: Cochleovestibular Dysfunction
      direction: UNCHANGED
      interpretation: Normal thresholds at the tested young ages.
      evidence:
      - reference: PMID:23226461
        reference_title: Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: The analysis of auditory brainstem responses (ABR) showed that mtl and bsd homozygotes are deaf, whereas heterozygous and wildtype littermates have normal hearing.
        explanation: At tested young ages, homozygotes had no ABR up to the stimulus ceiling while heterozygotes had normal thresholds; this is an age- and allele-bounded comparison.
  evidence:
  - reference: PMID:23226461
    reference_title: Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: The characterization of these two new Lmx1a alleles highlights the critical role of this gene in the development of the cochlea and vestibular system.
    explanation: The authors' own summary of what these alleles establish.
- name: Lmx1a drJ functional-null mouse
  species: Mouse
  genotype: Lmx1a drJ/drJ with heterozygous and wild-type controls
  publication: PMID:19540218
  description: The drJ functional-null allele disrupts sensory/nonsensory boundaries and formation of the membranous labyrinth. Later work documents defective strial differentiation and endocochlear potential below 6 mV in homozygotes. The 2025 study explicitly measured wild-type, heterozygous and homozygous animals at P12 and P21, six per age/genotype. Loss of cochlear melanoblast labeling does not establish whether the cells died or changed location.
  genes:
  - preferred_term: LMX1A
    term:
      id: hgnc:6653
      label: LMX1A
  modeled_mechanisms:
  - target: Impaired Strial Differentiation
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: Establishes the null-model strial phenotype underlying the candidate human mechanism.
    limitations: The strong phenotype is biallelic and developmental. Human heterozygous strial physiology and a late-life heterozygote time course are not established by this experiment.
    evidence:
    - reference: PMID:40109362
      reference_title: Lmx1a is essential for marginal cell differentiation and stria vascularis formation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: we observe a lack of proteins specific to the stria vascularis, such as BSND and KCNQ1 in marginal cells and CD44 in intermediate cells.
      explanation: Strial differentiation-marker loss in the homozygous model.
      directness: INDIRECT
    readouts:
    - name: Strial differentiation markers
      target: Impaired Strial Differentiation
      direction: DECREASED
      interpretation: Loss of marginal/intermediate markers in the homozygous mutant.
      evidence:
      - reference: PMID:40109362
        reference_title: Lmx1a is essential for marginal cell differentiation and stria vascularis formation.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: we observe a lack of proteins specific to the stria vascularis, such as BSND and KCNQ1 in marginal cells and CD44 in intermediate cells.
        explanation: Strial differentiation-marker loss in the homozygous model.
        directness: INDIRECT
  - target: Reduced Endocochlear Potential
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: Measures endocochlear-potential failure in the homozygous functional-null model.
    limitations: The strong phenotype is biallelic and developmental. Human heterozygous strial physiology and a late-life heterozygote time course are not established by this experiment.
    evidence:
    - reference: PMID:40109362
      reference_title: Lmx1a is essential for marginal cell differentiation and stria vascularis formation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: we measured the EP at P12 (during development) and P21 (mature EP) and confirmed a total absence of EP remained at less than 6-mV
      explanation: The source calls EP absent but reports a residual measurement below 6 mV, not exact mathematical zero.
      directness: INDIRECT
    readouts:
    - name: Homozygous endocochlear potential at P12 and P21
      target: Reduced Endocochlear Potential
      direction: DECREASED
      interpretation: Below 6 mV; wild-type and heterozygous groups were measured in the same study.
      evidence:
      - reference: PMID:40109362
        reference_title: Lmx1a is essential for marginal cell differentiation and stria vascularis formation.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: We examined the functional status of the Lmx1a mutant stria by comparing wild-type, heterozygote, and mutant EP (endocochlear potential) at P12 and P21. Six animals from each age/genotype were used.
        explanation: Directly establishes the heterozygous comparison that the previous entry incorrectly called absent.
      - reference: PMID:40109362
        reference_title: Lmx1a is essential for marginal cell differentiation and stria vascularis formation.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: we measured the EP at P12 (during development) and P21 (mature EP) and confirmed a total absence of EP remained at less than 6-mV
        explanation: The source calls EP absent but reports a residual measurement below 6 mV, not exact mathematical zero.
        directness: INDIRECT
  evidence:
  - reference: PMID:19540218
    reference_title: Lmx1a maintains proper neurogenic, sensory, and non-sensory domains in the mammalian inner ear.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Furthermore, aberrant and ectopic sensory organs are observed; most striking among these is vestibular-like hair cells located in the cochlear duct.
    explanation: The boundary-violation phenotype that establishes Lmx1a's selector-gene role, and the clearest illustration of how different the null is from the human disease.
  - reference: PMID:40109362
    reference_title: Lmx1a is essential for marginal cell differentiation and stria vascularis formation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: The transcription factor Lmx1a is widely expressed during early inner ear development, and mice lacking Lmx1a expression exhibit fusion of cochlear and vestibular hair cells and fail to form the ductus reuniens and the endolymphatic sac.
    explanation: The developmental scope of Lmx1a loss in the null, summarised by the same group.
- name: Lmx1a and Lmx1b central auditory allelic series
  species: Mouse
  genotype: Lmx1a drJ functional null with Lmx1b null alleles; Lmx1a-/-, Lmx1a-/-;Lmx1b+/-, double heterozygotes and controls
  publication: PMID:41991696
  description: At P14, Lmx1a-null mice had reduced excitatory-neuron densities in dorsal/ventral cochlear nuclei, aggravated by loss of one Lmx1b copy; double heterozygotes were normal for those measures. Roof-plate Bmp6 expression and Atoh1-positive progenitors were reduced at embryonic stages. P0/P14 apoptosis staining did not increase, without excluding other ages. Central projection defects could also reflect inner-ear abnormalities; tissue-specific conditional studies were proposed rather than performed.
  genes:
  - preferred_term: LMX1A
    term:
      id: hgnc:6653
      label: LMX1A
  evidence:
  - reference: PMID:41991696
    reference_title: An Lmx1a/b allelic series reveals the role of Lmx1 genes in cochlear nuclei development.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Loss of Lmx1a reduced distinct populations of excitatory neurons in dorsal (DCN) and ventral (VCN) cochlear nuclei and their innervation from the inner ear.
    explanation: Central auditory phenotype in the Lmx1a-null allelic series; not demonstrated in human heterozygotes.
    directness: INDIRECT
  modeled_mechanisms:
  - target: Cochleovestibular Dysfunction
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: Demonstrates an additional central developmental requirement for Lmx1a, with partial Lmx1b redundancy.
    limitations: Biallelic disruption differs from DFNA7, and normal double-heterozygous counts argue against simply equating these findings with human haploinsufficiency. No patient central lesion is established.
    evidence:
    - reference: PMID:41991696
      reference_title: An Lmx1a/b allelic series reveals the role of Lmx1 genes in cochlear nuclei development.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Loss of Lmx1a reduced distinct populations of excitatory neurons in dorsal (DCN) and ventral (VCN) cochlear nuclei and their innervation from the inner ear.
      explanation: Central auditory phenotype in the Lmx1a-null allelic series; not demonstrated in human heterozygotes.
      directness: INDIRECT
    readouts:
    - name: Excitatory-neuron density in cochlear nuclei
      target: Cochleovestibular Dysfunction
      direction: DECREASED
      interpretation: Reduced in Lmx1a-null mice and further reduced with an additional lost Lmx1b copy.
      evidence:
      - reference: PMID:41991696
        reference_title: An Lmx1a/b allelic series reveals the role of Lmx1 genes in cochlear nuclei development.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: Loss of Lmx1a reduced distinct populations of excitatory neurons in dorsal (DCN) and ventral (VCN) cochlear nuclei and their innervation from the inner ear.
        explanation: Central auditory phenotype in the Lmx1a-null allelic series; not demonstrated in human heterozygotes.
        directness: INDIRECT
discussions:
- discussion_id: lmx1a_dominant_model_gap
  kind: HUMAN_MODEL_MISMATCH
  prompt: Which endogenous heterozygous LMX1A alleles reproduce human hearing loss, and do developmental and postdevelopmental requirements differ?
  attaches_to:
  - pathophysiology#Cochleovestibular Dysfunction
  - animal_models#Lmx1a mutanlallemand and Belly Spot and Deafness mice
  - animal_models#Lmx1a drJ functional-null mouse
  rationale: Young heterozygous mtl/bsd mice had normal hearing, while biallelic mutants had major malformations. The 2025 drJ study includes heterozygote EP measurements, and the 2026 central study includes double heterozygotes. These are informative negative or comparator observations, not lifelong exclusions. Human onset includes congenital and adult cases. Serial heterozygous patient-allele knock-in studies could establish a closer model; temporally controlled perturbation and rescue are needed to distinguish developmental from ongoing requirements.
  evidence:
  - reference: PMID:23226461
    reference_title: Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: The analysis of auditory brainstem responses (ABR) showed that mtl and bsd homozygotes are deaf, whereas heterozygous and wildtype littermates have normal hearing.
    explanation: Normal heterozygous ABR at tested ages; no species-wide or lifelong conclusion follows.
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although Lmx1a mouse mutants demonstrate neurological, skeletal, pigmentation and reproductive system abnormalities, no syndromic features were present in the participating subjects of either family.
    explanation: No syndromic findings in these participating families, despite broader null-mouse phenotypes.
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Alternatively, minor cochleovestibular developmental abnormalities could eventually lead to the progressive phenotype seen in the families.
    explanation: A competing developmental interpretation retained by the founding authors.
  proposed_experiments:
  - experiment_id: exp_dfna7_aged_heterozygous_lmx1a_abr
    name: Patient-allele knock-in and temporally controlled Lmx1a studies
    description: Compare heterozygous patient-allele knock-ins with null heterozygotes and wild-type littermates through aging, with ABR/DPOAE, strial physiology and histology. Use embryonic versus postdevelopmental perturbation and rescue to test timing. Late decline alone cannot distinguish subtle developmental injury from an ongoing requirement.
    readouts:
    - name: Longitudinal auditory thresholds
      target: pathophysiology#Cochleovestibular Dysfunction
      interpretation: Defines allele- and age-dependent dysfunction; normal results constrain the particular model without excluding human disease.
    - name: Response to temporally restricted perturbation and rescue
      target: pathophysiology#Cochleovestibular Dysfunction
      interpretation: Timing-dependent phenotypes and rescue would distinguish developmental from ongoing requirements more directly than endpoint histology.
  status: OPEN
- discussion_id: lmx1a_asymmetry_mechanism
  kind: KNOWLEDGE_GAP
  prompt: What contributes to interaural asymmetry and intrafamilial variability in LMX1A-related hearing loss?
  attaches_to:
  - phenotypes#Asymmetric Sensorineural Hearing Loss
  - pathophysiology#Cochleovestibular Dysfunction
  rationale: A germline variant does not by itself explain differences between ears or relatives. Developmental variation, local cellular responses, age and additional genetic or acquired factors are candidates, not established causes. The 2026 study proposes stress-related asymmetry but lacks longitudinal audiometry and imaging of other affected relatives; the 2022 series also describes fluctuation with possible Meniere disease in one carrier. Neither observation proves a shared modifier. Prospective ear-specific assessment is needed.
  evidence:
  - reference: PMID:35711095
    reference_title: 'Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It is important to note that asymmetric hearing loss was identified in all probands and most affected individuals, although the extent of asymmetry varied.
    explanation: Establishes the phenomenon as near-universal in the series while explicitly noting that its degree varies, which is the variability the gap is about.
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinical manifestations exhibited significant intrafamilial phenotypic variability, with hearing loss (HL) severity ranging from mild to profound, and onset varying from infancy to mid-adulthood.
    explanation: Between-individual variability on one allele within one family, the same puzzle as between-ear asymmetry seen at a different scale, and equally unexplained by dosage.
  status: OPEN
- discussion_id: dfna7_locus_to_gene_assignment
  kind: KNOWLEDGE_GAP
  prompt: Has the molecular cause of the original Norwegian DFNA7 linkage family been identified?
  attaches_to:
  - disease#Autosomal Dominant Nonsyndromic Hearing Loss 7
  - genetic#LMX1A
  rationale: The 1996 study mapped a 22-cM interval on 1q21-q23 without identifying a causal variant. The retrieved later LMX1A reports establish the dominant gene–disease relationship in other families, and ClinGen classified it as definitive in 2025. They do not solve the original Norwegian pedigree. High-frequency hearing loss in that family is compatible with later LMX1A presentations and is not evidence for a different disease.
  evidence:
  - reference: PMID:8842739
    reference_title: Identification of a new locus for autosomal dominant non-syndromic hearing impairment (DFNA7) in a large Norwegian family.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Analysis of recombinant individuals maps the deafness gene (DFNA7) to a 22 cM region between D1S104 and D1S466.
    explanation: The locus definition. A 22 cM interval is what the DFNA7 label originally denoted, and the founding paper stops at localisation.
  - reference: PMID:8842739
    reference_title: Identification of a new locus for autosomal dominant non-syndromic hearing impairment (DFNA7) in a large Norwegian family.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The region contains several attractive candidate genes.
    explanation: The founding authors' own statement that the interval held multiple candidates, which is why positional plausibility alone does not settle the assignment.
  - reference: PMID:8842739
    reference_title: Identification of a new locus for autosomal dominant non-syndromic hearing impairment (DFNA7) in a large Norwegian family.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The present report describes a large Norwegian family with autosomal dominant non-syndromic, progressive high tone hearing loss with linkage to 1q21-q23.
    explanation: The original high-tone progressive phenotype overlaps later LMX1A families; it is not a phenotypic contradiction.
  - reference: PMID:29754270
    reference_title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here, we identified heterozygous pathogenic missense variants of LMX1A in two families of Dutch origin with progressive nonsyndromic hearing impairment (HI), using whole exome sequencing.
    explanation: The later gene association was established in unrelated Dutch pedigrees.
  - reference: CGGV:assertion_163f8708-7d3b-424a-826a-76e37260745c-2025-04-22T160000.000Z
    reference_title: LMX1A / autosomal dominant nonsyndromic hearing loss (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: there is definitive evidence supporting the relationship between LMX1A and autosomal dominant nonsyndromic deafness.
    explanation: ClinGen Hearing Loss GCEP classification approved at the 16 April 2025 meeting and recorded 22 April 2025; this concerns the dominant gene–disease relationship.
    quote_role: REVIEW_SYNTHESIS
  status: OPEN
mechanistic_hypotheses:
- hypothesis_group_id: lmx1a_cellular_stress
  hypothesis_label: LMX1A dysfunction may impair auditory cellular homeostasis
  status: EMERGING
  description: RNA sequencing and exploratory DIA proteomics compared mutant and wild-type Lmx1a overexpression in HEI-OC1 cells. Enrichment implicated immune signaling, ER stress, ionic/metabolic regulation and synaptic programs. These are cell-line signatures, not demonstrated inflammation, excitotoxicity, infection or necroptosis in DFNA7 patients. The authors explicitly acknowledge nonspecific responses to artificial overexpression. Earlier C-terminal-domain apoptosis assays indicate a role in survival regulation but, in the accessible abstract, do not establish increased patient hair-cell death. Native-cell perturbation and rescue are needed to assign downstream causal steps.
  evidence:
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: This dual‐validation approach revealed synchronized enrichment in proteostasis and ER stress networks
    explanation: Integrated RNA/protein enrichment provides an exploratory mechanistic lead.
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: we cannot preclude the possibility that these alterations partially reflect an intrinsic, nonspecific response of the artificial HEI‐OC1 overexpression system to in vitro manipulation.
    explanation: The study’s explicit limitation prevents promoting these signatures to patient mechanisms.
  - reference: PMID:36519758
    reference_title: 'A novel frameshift variant of LMX1A that leads to autosomal dominant non-syndromic sensorineural hearing loss: functional characterization of the C-terminal domain in LMX1A.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Furthermore, apoptosis assays suggested that the C-terminal domain of the LMX1A was important for mediating apoptosis in the cochlear hair cells.
    explanation: Accessible abstract supports a C-terminal role in apoptosis assays; it does not establish increased apoptosis in human cochlear hair cells.
experimental_models:
- name: HEK293 LMX1A transactivation reporter
  experimental_model_type: CELL_LINE
  publication: PMID:42253511
  description: Transient wild-type and mutant LMX1A expression with INS-promoter firefly luciferase and Renilla normalization. Five dominant variants reduced activity; recessive p.Ile369Thr retained wild-type-like activity. WT/mutant titration was performed for p.Phe135LeufsTer3.
  evidence:
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Each well received 0.1 μg pGL4.12‐INS‐luc, 0.1 μg either WT or mutant LMX1A expression plasmid
    explanation: HEK293 reporter uses an INS-promoter construct, not a defined native cochlear target.
  modeled_mechanisms:
  - target: Reduced Transactivation of LMX1A Target Genes
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: Directly measures reporter transactivation in a nonauditory cell line.
    limitations: Overexpression and the INS promoter do not reconstruct native auditory dosage or downstream target selection.
    evidence:
    - reference: PMID:42253511
      reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Each well received 0.1 μg pGL4.12‐INS‐luc, 0.1 μg either WT or mutant LMX1A expression plasmid
      explanation: HEK293 reporter uses an INS-promoter construct, not a defined native cochlear target.
    readouts:
    - name: Normalized INS-promoter luciferase activity
      target: Reduced Transactivation of LMX1A Target Genes
      direction: DECREASED
      interpretation: Reduced for the five tested dominant alleles, not for recessive p.Ile369Thr.
      evidence:
      - reference: PMID:42253511
        reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: our functional assays demonstrated a profound loss of transactivation capacity for multiple LMX1A variants affecting the LIM domains and homeodomains
        explanation: Reporter result; the adjacent source sentence explicitly distinguishes the recessive allele.
- name: HEI-OC1 Lmx1a overexpression and RNA-decay model
  experimental_model_type: CELL_LINE
  publication: PMID:42253511
  description: Mouse auditory cell-line transfection with wild-type or c.405delT Lmx1a. RNA sequencing and exploratory DIA proteomics assess downstream signatures; Actinomycin D chase measures transfected RNA stability. This is not patient cochlear tissue or an endogenous heterozygous knock-in.
  evidence:
  - reference: PMID:42253511
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Actinomycin D (ActD) chase assays were performed in transfected HEI‐OC1 cells to evaluate mRNA stability.
    explanation: Defines the transfected RNA-decay system.
  notes: RNA-seq is deposited as GSE299979. The source warns that omics signatures may reflect nonspecific manipulation or overexpression stress; necroptosis enrichment is not a measured death mechanism.
datasets:
- accession: geo:GSE299979
  title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7
  data_type: BULK_RNA_SEQ
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  publication: PMID:42253511
  description: RNA sequencing of HEI-OC1 cells expressing wild-type or c.405delT Lmx1a. The paper presents three biological replicates per group.
  genes:
  - preferred_term: LMX1A
    term:
      id: hgnc:6653
      label: LMX1A
  notes: Exploratory overexpression comparison; the GEO summary emphasizes neurodevelopmental/synaptic/mitochondrial pathways, whereas the final paper also emphasizes immune and ER-stress enrichment. Neither summary is patient-tissue evidence. No proteomics accession is asserted.
  evidence:
  - reference: GEO:GSE299979
    reference_title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: RNA sequencing (RNA-seq) of HEI-OC1 cells
    explanation: Generated GEO record confirms the system and assay; the primary paper supplies the experimental interpretation.
external_assertions:
- name: ClinGen LMX1A dominant hearing-loss validity
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: HGNC:6653
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_163f8708-7d3b-424a-826a-76e37260745c-2025-04-22T160000.000Z
  description: Definitive association; April 2025 curation.
  evidence:
  - reference: CGGV:assertion_163f8708-7d3b-424a-826a-76e37260745c-2025-04-22T160000.000Z
    reference_title: LMX1A / autosomal dominant nonsyndromic hearing loss (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: there is definitive evidence supporting the relationship between LMX1A and autosomal dominant nonsyndromic deafness.
    explanation: ClinGen Hearing Loss GCEP classification approved at the 16 April 2025 meeting and recorded 22 April 2025; this concerns the dominant gene–disease relationship.
    quote_role: REVIEW_SYNTHESIS
notes: This entry is restricted to dominant LMX1A-related disease. No uniform patient cell type, structural lesion or progression rate is assumed. ClinicalTrials.gov searches on 23 September 2026 found no DFNA7 study; two LMX1A matches concerned unrelated cognitive-training studies (NCT04792528 and NCT02602418). GeneReviews general guidance is extrapolated where disease-specific outcomes are sparse. Its PMID:20301607 cache remains abstract-only after retrieval; the generated tagged Bookshelf URL cache supplies the full chapter and is the same source, not independent evidence.
references:
- reference: PMID:29754270
  title: Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
- reference: PMID:36519758
  title: 'A novel frameshift variant of LMX1A that leads to autosomal dominant non-syndromic sensorineural hearing loss: functional characterization of the C-terminal domain in LMX1A.'
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
  title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
  tags:
  - GeneReviews
- reference: PMID:42253511
  title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
- reference: PMID:32840933
  title: Novel genotype-phenotype correlation of functionally characterized LMX1A variants linked to sensorineural hearing loss.
- reference: PMID:35254497
  title: Update on CD164 and LMX1A genes to strengthen their causative role in autosomal dominant hearing loss.
- reference: PMID:35711095
  title: 'Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants.'
- reference: PMID:38465368
  title: Structural insights into the recognition of the A/T-rich motif in target gene promoters by the LMX1a homeobox domain.
- reference: PMID:40109362
  title: Lmx1a is essential for marginal cell differentiation and stria vascularis formation.
- reference: PMID:19540218
  title: Lmx1a maintains proper neurogenic, sensory, and non-sensory domains in the mammalian inner ear.
- reference: PMID:36140227
  title: 'Genetic Load of Alternations of Transcription Factor Genes in Non-Syndromic Deafness and the Associated Clinical Phenotypes: Experience from Two Tertiary Referral Centers.'
- reference: CGGV:assertion_163f8708-7d3b-424a-826a-76e37260745c-2025-04-22T160000.000Z
  title: LMX1A / autosomal dominant nonsyndromic hearing loss (Definitive)
- reference: PMID:41078281
  title: A Novel Missense Variant in LMX1A Leads to Autosomal Dominant Nonsyndromic Hearing Loss.
- reference: PMID:29971487
  title: A variant in LMX1A causes autosomal recessive severe-to-profound hearing impairment.
- reference: PMID:23226461
  title: Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects.
- reference: PMID:41991696
  title: An Lmx1a/b allelic series reveals the role of Lmx1 genes in cochlear nuclei development.
- reference: PMID:8842739
  title: Identification of a new locus for autosomal dominant non-syndromic hearing impairment (DFNA7) in a large Norwegian family.
- reference: GEO:GSE299979
  title: A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7
- reference: PMID:20301607
  title: Genetic Hearing Loss Overview.
  tags:
  - GeneReviews
📚

References & Deep Research

References

19
PMID:29754270
Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction.
No top-level findings curated for this source.
PMID:36519758
A novel frameshift variant of LMX1A that leads to autosomal dominant non-syndromic sensorineural hearing loss: functional characterization of the C-terminal domain in LMX1A.
No top-level findings curated for this source.
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
No top-level findings curated for this source.
PMID:42253511
A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7.
No top-level findings curated for this source.
PMID:32840933
Novel genotype-phenotype correlation of functionally characterized LMX1A variants linked to sensorineural hearing loss.
No top-level findings curated for this source.
PMID:35254497
Update on CD164 and LMX1A genes to strengthen their causative role in autosomal dominant hearing loss.
No top-level findings curated for this source.
PMID:35711095
Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants.
No top-level findings curated for this source.
PMID:38465368
Structural insights into the recognition of the A/T-rich motif in target gene promoters by the LMX1a homeobox domain.
No top-level findings curated for this source.
PMID:40109362
Lmx1a is essential for marginal cell differentiation and stria vascularis formation.
No top-level findings curated for this source.
PMID:19540218
Lmx1a maintains proper neurogenic, sensory, and non-sensory domains in the mammalian inner ear.
No top-level findings curated for this source.
PMID:36140227
Genetic Load of Alternations of Transcription Factor Genes in Non-Syndromic Deafness and the Associated Clinical Phenotypes: Experience from Two Tertiary Referral Centers.
No top-level findings curated for this source.
CGGV:assertion_163f8708-7d3b-424a-826a-76e37260745c-2025-04-22T160000.000Z
LMX1A / autosomal dominant nonsyndromic hearing loss (Definitive)
No top-level findings curated for this source.
PMID:41078281
A Novel Missense Variant in LMX1A Leads to Autosomal Dominant Nonsyndromic Hearing Loss.
No top-level findings curated for this source.
PMID:29971487
A variant in LMX1A causes autosomal recessive severe-to-profound hearing impairment.
No top-level findings curated for this source.
PMID:23226461
Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects.
No top-level findings curated for this source.
PMID:41991696
An Lmx1a/b allelic series reveals the role of Lmx1 genes in cochlear nuclei development.
No top-level findings curated for this source.
PMID:8842739
Identification of a new locus for autosomal dominant non-syndromic hearing impairment (DFNA7) in a large Norwegian family.
No top-level findings curated for this source.
GEO:GSE299979
A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7
No top-level findings curated for this source.
PMID:20301607
Genetic Hearing Loss Overview.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Autosomal Dominant Nonsyndromic Hearing Loss 7 (DFNA7, LMX1A) · 2026-08-28T18:45:48Z · View source

De novo curation of DFNA7 (MONDO:0011074, LMX1A hgnc:6653) from the stub queue. entry_type decided as DISEASE: a single causal gene, no MONDO descendants, and one conserved pathograph running from LMX1A haploinsufficiency through reduced transactivation of target genes to a maintenance failure of cochleovestibular function. Not a subtype of any existing dismech entry; LMX1A previously appeared in kb/ only as an RFX6 target gene in Mitchell-Riley_Syndrome, which is not disease coverage of DFNA7. The organising point of the entry is the human/mouse dissociation. Every Lmx1a animal model of deafness is a homozygous null with gross labyrinthine malformation, while human DFNA7 is a heterozygous, imaging-normal ear that deteriorates; mouse heterozygotes hear normally. Both mouse models are therefore curated with FAILS_TO_RECAPITULATE links against the human maintenance node alongside PARTIALLY_RECAPITULATES against the transcriptional node, and a HUMAN_MODEL_MISMATCH discussion carries the unresolved translational question with a proposed aged-heterozygote experiment. A second KNOWLEDGE_GAP records that nothing in the curated mechanism explains the characteristic interaural asymmetry. Evidence: 11 references fetched with just fetch-reference; 53/53 snippets verified against the local cache. Haploinsufficiency rather than a dominant-negative effect is supported by three independent groups. The recessive LMX1A allele (PMID:29971487) is curated in genetic: as a boundary marker with an explicit note that the recessive phenotype is a separate MONDO concept not covered here. Asymmetric hearing loss is bound to HP:0000407 with the asymmetry carried by preferred_term because HPO has no asymmetric-hearing term; recorded in notes. Hearing-aid fitting is left with an unbound free-text treatment_term for the same reason as DFNB106. Cochlear implantation and speech rehabilitation are deliberately not curated because no DFNA7-specific report documents them. Deep research: a falcon report was run and preflighted against MONDO:0011074. Verdict WARN, not FAIL, and inspected: the gene profile is LMX1A=50 with the next gene at 3, and the OMIM mismatch comes from the report quoting the LMX1A gene MIM 600298 and the broad concept MIM 500008 while explicitly stating it could not verify a disease-specific OMIM. Not Named Entity Confusion. The entry was nevertheless curated from primary sources and every snippet re-verified against the cache rather than lifted from the report. Validation: just validate exit 0, just validate-terms exit 0, just check-entity-refs exit 0, just check-duplicate-keys exit 0.

Falcon ▸
Autosomal Dominant Nonsyndromic Hearing Loss 7 (DFNA7): Disease-Characteristics Report
Edison Scientific Literature 28 citations 2026-08-28T11:41:47.662726

Autosomal Dominant Nonsyndromic Hearing Loss 7 (DFNA7): Disease-Characteristics Report

Executive summary

Autosomal dominant nonsyndromic hearing loss 7 (DFNA7) is a rare Mendelian sensorineural hearing-loss disorder caused by heterozygous pathogenic variants in LMX1A, a LIM-homeodomain transcription-factor gene at 1q23.3. The best-supported phenotype is bilateral but frequently asymmetric sensorineural hearing loss (SNHL), with congenital through adult onset, usually a downsloping/high-frequency audiogram, variable mild-to-profound severity, and frequent progression. Vestibular dysfunction occurs in a subset and affected individuals otherwise lack a consistent syndromic phenotype. Human functional studies support haploinsufficiency, while mouse models establish LMX1A roles in cochlear and vestibular patterning, sensory-epithelium segregation, stria-vascularis differentiation, and generation of the endocochlear potential. No DFNA7-specific disease-modifying therapy or clinical trial was identified; present care consists of surveillance, hearing aids, cochlear implantation when indicated, vestibular management, communication support, and genetic counseling. (wesdorp2018heterozygousmissensevariants pages 8-9, wesdorp2018heterozygousmissensevariants pages 1-2, lee2020novelgenotype–phenotypecorrelation pages 2-4, jo2022geneticloadof pages 8-10)

Domain Key findings Ontology suggestions Evidence strength/type
Identity / disease class Autosomal dominant nonsyndromic hearing loss 7 (DFNA7) is a Mendelian, nonsyndromic sensorineural hearing-loss entity associated with LMX1A; Open Targets lists MONDO:0011074 for this disease-target association. Evidence is from aggregated disease resources plus small family-based human studies, not EHR-derived population datasets. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A, alde2023autosomaldominantnonsyndromic pages 3-4) MONDO:0011074; nonsyndromic hearing impairment concept Moderate; curated disease-resource + human genetic studies
Locus / gene Cytogenetic location reported as 1q23.3; gene LMX1A encodes a LIM-homeobox transcription factor important for inner-ear development and maintenance. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A, alde2023autosomaldominantnonsyndromic pages 3-4, lee2020novelgenotype–phenotypecorrelation pages 1-2) Gene: LMX1A; UBERON: inner ear, cochlea, vestibular system Strong for gene-disease association; human + model evidence
Inheritance Predominantly autosomal dominant; several families show vertical transmission, and de novo heterozygous variants have also been reported. (wesdorp2018heterozygousmissensevariants pages 1-2, lee2020novelgenotype–phenotypecorrelation pages 2-4, jo2022geneticloadof pages 8-10) HP: Autosomal dominant inheritance Strong; human pedigree/segregation evidence
Core phenotype Core presentation is sensorineural hearing loss (SNHL), usually bilateral but often asymmetric, commonly with downsloping/high-frequency configuration and variable severity from mild to profound. Suggested HPO terms: hearing impairment, sensorineural hearing impairment, asymmetric hearing impairment, progressive hearing impairment, high-frequency/sloping audiogram. (wesdorp2018heterozygousmissensevariants pages 8-9, jo2022geneticloadof pages 8-10, alde2023autosomaldominantnonsyndromic pages 3-4) HPO suggestions: sensorineural hearing impairment; progressive hearing impairment; asymmetric hearing impairment; high-frequency hearing impairment Strong; human clinical cohorts
Onset / temporal course Onset is highly variable: congenital/prelingual cases and postlingual cases are both reported; 2023 review summarizes onset from 1st–6th decade with progressive course. In the 2018 series, onset ranged from congenital to 35 years and was often in the 2nd–3rd decade. Disease is typically lifelong, not remitting. (alde2023autosomaldominantnonsyndromic pages 3-4, wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 8-9) HPO suggestions: congenital onset; childhood onset; adult onset; progressive course Strong; review + primary human data
Vestibular involvement Vestibular dysfunction is a recurrent but variable feature: the 2018 study states about half of affected individuals had vestibular dysfunction/symptoms; abnormalities included absent cVEMPs and caloric abnormalities, with symptoms appearing in adulthood and seeming progressive. In the 2022 cohort, one patient had hearing fluctuation with intermittent vertigo/headache suggestive of Menière-like episodes. (wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 4-6, jo2022geneticloadof pages 8-10) HPO suggestions: vestibular dysfunction, vertigo, abnormal caloric test, absent vestibular evoked myogenic potentials Moderate-strong; small human cohorts with formal vestibular testing
Key pathogenic variants Reported heterozygous disease-associated variants include c.290G>C (p.Cys97Ser), c.721G>C (p.Val241Leu), c.595A>G (p.Arg199Gly), c.622C>T (p.Arg208*), c.887dup (p.Gln297Thrfs*41), c.719A>G (p.Gln240Arg), c.721G>A (p.Val241Met), and c.331del (p.Gln111Argfs*7). Most are ultra-rare/absent in population databases in the cited cohorts. (wesdorp2018heterozygousmissensevariants pages 1-2, lee2020novelgenotype–phenotypecorrelation pages 2-4, jo2022geneticloadof pages 4-5, jo2022geneticloadof pages 8-10, wesdorp2018heterozygousmissensevariants pages 4-6) Variant classes: missense, nonsense, frameshift; germline heterozygous variants Strong for listed reported variants; human molecular studies
Mechanism / pathophysiology Human functional data support haploinsufficiency rather than dominant-negative effect for dominant LMX1A hearing loss. Reduced transcriptional activity correlates with more severe phenotype; p.Arg199Gly had near-abolished activity and severe congenital SNHL, whereas p.Cys97Ser/p.Val241Leu retained more activity and caused later progressive NSHL. Upstream/downstream developmental links from models include regulation involving Lmo4, Bmp6, Atoh1, Pax2, Wnt-related patterning, and strial differentiation markers. (lee2020novelgenotype–phenotypecorrelation pages 2-4, lee2020novelgenotype–phenotypecorrelation pages 1-2, huang2018reciprocalnegativeregulation pages 1-2, iskusnykh2026anlmx1aballelic pages 1-2, renauld2025lmx1aisessential pages 1-2, nichols2008lmx1aisrequired pages 11-12) GO suggestions: DNA-binding transcription factor activity; inner ear development; sensory epithelium development; stria vascularis development Strong for transcriptional dysfunction/haploinsufficiency; human in vitro + mouse developmental models
Anatomy / tissues / cell types Primary anatomy: cochlea, organ of Corti, stria vascularis, Reissner’s membrane, endolymphatic duct/sac, vestibular organs, and spiral ganglion/cerebellar-brainstem auditory circuitry in models. Cell-type suggestions include hair cells, marginal cells, intermediate cells, spiral ganglion neurons, and non-sensory epithelial cells. Single-cell evidence identified an Lmx1a-positive type I spiral ganglion neuron population in mouse cochlea. (renauld2025lmx1aisessential pages 1-2, chizhikov2021lmx1aandlmx1b pages 1-2, nichols2008lmx1aisrequired pages 11-12, grandi2020singlecellrnaanalysis pages 1-2) UBERON suggestions: cochlea, organ of Corti, stria vascularis, vestibular labyrinth; CL suggestions: hair cell, marginal cell, intermediate cell, spiral ganglion neuron; GO CC suggestions: nucleus Moderate-strong; mostly model-organism anatomy/cell evidence
Diagnostics Current diagnosis is based on audiologic phenotyping, serial follow-up for progression/asymmetry, vestibular testing when symptomatic, temporal-bone CT to exclude malformations/other causes, and molecular testing using hearing-loss gene panels or WES with segregation/ACMG interpretation; WGS is a reasonable escalation in unsolved hearing-loss cases generally, but no DFNA7-specific testing guideline was found. (wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 4-6, jo2022geneticloadof pages 8-10) HPO suggestions for workup: abnormal auditory brainstem response; abnormal vestibular testing Moderate; disease-specific cohort methods + general hearing-loss practice inference
Treatment / real-world care No DFNA7-specific drug or gene therapy was identified. Real-world management is supportive: hearing aids for milder/moderate disease and cochlear implantation (CI) for advanced loss. In the 2022 LMX1A series, one patient underwent unilateral CI with significant speech-perception improvement at 3 and 6 months post-op; the same paper notes favorable CI outcomes in LMX1A-related cases. (jo2022geneticloadof pages 8-10, jo2022geneticloadof pages 4-5) NCIT suggestions: hearing aid device; cochlear implantation; vestibular rehabilitation; genetic counseling Moderate; small human rehabilitation cohort
Epidemiology / population Disease-specific prevalence and incidence are not available. Evidence comes from very small reported series: 2018 described two Dutch families; 2022 identified nine patients from six LMX1A-associated families in two tertiary centers. No robust penetrance, sex ratio, founder mutation, carrier frequency, or geographic prevalence data were found. (wesdorp2018heterozygousmissensevariants pages 1-2, jo2022geneticloadof pages 8-10) Rare disease; familial autosomal dominant hearing loss Limited; case-series level
Environmental factors / modifiers No validated DFNA7-specific environmental risk or protective factors were identified. The 2018 study excluded obvious acquired causes of hearing loss in examined subjects, but formal gene-environment interactions remain unproven. General hearing-conservation advice is still clinically sensible but is not DFNA7-specific evidence. (wesdorp2018heterozygousmissensevariants pages 4-6, wesdorp2018heterozygousmissensevariants pages 8-9) HPO/Exposure suggestions not disease-specific Limited; absence-of-evidence statement
Model organisms Mouse Lmx1a null/dreher models show severe cochlear and vestibular malformations, loss/fusion of sensory epithelia, abnormal stria vascularis formation, absent endocochlear potential, and deafness; these models are mechanistically informative but more severe than human dominant DFNA7. Heterozygous mice may have normal hearing, highlighting translational limitations. (wesdorp2018heterozygousmissensevariants pages 8-9, renauld2025lmx1aisessential pages 1-2, chizhikov2021lmx1aandlmx1b pages 1-2, nichols2008lmx1aisrequired pages 11-12) NCBI Taxon suggestion: Mus musculus; phenotype suggestions: deafness, vestibular dysfunction Strong for mechanism; indirect for exact human phenotype
Evidence gaps / curation cautions Gaps include: original historical linkage details not fully retrieved here; no disease-specific epidemiology; no validated penetrance estimates; no confirmed modifier genes, protective factors, omics biomarkers, or epigenetic signatures; no registered DFNA7-specific interventional trial identified; and several ontology IDs beyond MONDO/HPO high-level terms would require manual validation before KB ingestion. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A, jo2022geneticloadof pages 8-10, qi2026genetherapyfor pages 4-6) Manual validation recommended for HPO/GO/CL/UBERON mappings Strong for identified gaps because evidence is sparse/no direct studies

Table: This table summarizes high-yield knowledge-base facts for autosomal dominant nonsyndromic hearing loss 7 associated with LMX1A, including phenotype, mechanism, diagnostics, treatment, and evidence gaps. It is designed as a compact curation aid grounded in the available cited human and model-organism evidence.

1. Disease information

Definition and identifiers

DFNA7 is an autosomal-dominant, predominantly nonsyndromic cochleovestibular disorder associated with monoallelic LMX1A variants. Open Targets records the association as MONDO:0011074, with LMX1A/ENSG00000162761 as its associated target. The cytogenetic locus is 1q23.3. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A, alde2023autosomaldominantnonsyndromic pages 3-4)

Recommended identifiers and labels are:

  • Preferred name: autosomal dominant nonsyndromic hearing loss 7
  • Synonyms: DFNA7; deafness, autosomal dominant 7; LMX1A-related autosomal dominant nonsyndromic hearing loss; LMX1A-related dominant hearing impairment
  • MONDO: MONDO:0011074
  • Gene: LMX1A, LIM homeobox transcription factor 1 alpha; Ensembl ENSG00000162761
  • Gene OMIM: LMX1A, MIM 600298
  • Broad phenotype OMIM concept: hereditary nonsyndromic hearing impairment, MIM 500008, as used in the foundational study; a disease-specific OMIM number was not independently verified from the retrieved evidence.
  • ICD-10/ICD-11 and MeSH: no DFNA7-specific billing or subject-heading code was established. Use the applicable broader sensorineural/genetic hearing-loss code, recording MONDO and molecular diagnosis separately.

The evidence is mainly aggregated disease-resource information and family-level research cohorts, not individual longitudinal EHR data. Open Targets integrates five disease-target evidence records; the primary human literature comprises small pedigrees and tertiary-center series. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A, jo2022geneticloadof pages 8-10)

2. Etiology, risk, protection, and gene–environment interaction

Causal factor

The primary cause is a germline heterozygous pathogenic or likely pathogenic LMX1A variant. Familial vertical transmission and de novo variants are both documented. In 2018, whole-exome sequencing identified p.Val241Leu and p.Cys97Ser in two Dutch families; p.Val241Leu was de novo, while p.Cys97Ser segregated with dominant hearing loss. The latter was absent from gnomAD in that study. (PMID: 29754270; published May 12, 2018; DOI/URL: https://doi.org/10.1007/s00439-018-1880-5). (wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 4-6)

Risk factors

  • Genetic: carrying a pathogenic heterozygous LMX1A allele is the major risk factor. Family history is important but not required because de novo disease occurs.
  • Age: risk of clinically detectable impairment increases with age for later-onset progressive alleles, although severe congenital presentations also occur.
  • Sex: no reproducible sex effect is established.
  • Family history: an affected parent implies an approximately 50% transmission probability for each pregnancy, assuming a constitutional heterozygous variant.
  • Environmental/acquired factors: no DFNA7-specific toxin, infection, diet, smoking exposure, or occupational risk has been demonstrated.

The 2018 cohort specifically investigated acquired causes and found none sufficient to explain the familial SNHL. One patient also had fenestral otosclerosis, illustrating that genetic and acquired/concurrent disorders can coexist. (wesdorp2018heterozygousmissensevariants pages 4-6)

Protective factors and gene–environment interaction

No protective LMX1A variants, modifier alleles, diet, medication, or lifestyle intervention has been validated. The marked intrafamilial variability led investigators to propose environmental and/or genetic modifiers, including expression of the remaining wild-type LMX1A allele, but this remains a hypothesis rather than an established interaction. Avoidance of excessive noise and ototoxic exposure is prudent hearing conservation, but it has not been shown specifically to alter DFNA7 penetrance or progression. (wesdorp2018heterozygousmissensevariants pages 8-9)

3. Phenotypes

Core hearing phenotype

The principal manifestation is sensorineural hearing impairment, usually bilateral and often asymmetric. The overall audiogram is commonly downsloping, reflecting greater high-frequency impairment. Severity ranges from mild to profound and varies substantially within and between families. Suggested terms include HP:0000365—hearing impairment, HP:0000407—sensorineural hearing impairment, progressive hearing impairment, high-frequency hearing impairment, and asymmetric hearing impairment; exact subordinate HPO identifiers should be ontology-validated before ingestion. (wesdorp2018heterozygousmissensevariants pages 8-9, alde2023autosomaldominantnonsyndromic pages 3-4, wesdorp2018heterozygousmissensevariants pages 4-6)

A 2023 DFNA review summarized DFNA7 as congenital-to-adult onset across the first through sixth decades, with a sloping, progressive phenotype and possible vertigo. This is a synthesis rather than a disease-specific natural-history cohort (published June 2023; DOI: https://doi.org/10.3390/biomedicines11061616). (alde2023autosomaldominantnonsyndromic pages 3-4)

Quantitative clinical evidence

In the 2022 two-center series, nine patients from six LMX1A families were identified. Five of nine had an interaural difference greater than 15 dB; reported mean asymmetry was 35.75 dB, range 15–65 dB. Three of four patients with follow-up audiometry had progressive hearing loss. Individual asymmetries in the clinical table included 18, 36, 45, and 61 dB. (PMID: 36519758; published August 30, 2022; DOI: https://doi.org/10.3390/biomedicines10092125). (jo2022geneticloadof pages 4-5, jo2022geneticloadof pages 8-10)

The 2018 report found onset from congenital to 35 years, usually in the second or third decade, with mild-to-profound, generally downsloping and progressive impairment. Its abstract states: “Large variability was observed in the age of onset (a)symmetry, severity and progression rate of HI.” (wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 4-6, wesdorp2018heterozygousmissensevariants pages 8-9)

Vestibular and related manifestations

Approximately half of affected members in the 2018 study displayed vestibular dysfunction and symptoms. Absent cervical vestibular-evoked myogenic potentials up to 100 dBnHL implicated saccular dysfunction; caloric and rotary-chair abnormalities were also observed. Adult onset and greater abnormalities in older individuals suggested progression, although longitudinal vestibular data were unavailable. Suggested HPO concepts are vestibular dysfunction, vertigo, abnormal caloric response, and absent cVEMP. (wesdorp2018heterozygousmissensevariants pages 8-9, wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 4-6)

One 2022 patient had fluctuating unilateral hearing, intermittent vertigo, and headache considered suggestive of coexisting Ménière disease. This should not be generalized as the canonical DFNA7 phenotype. (jo2022geneticloadof pages 8-10)

Syndromic exclusions and quality of life

Normal cognition and absence of consistent neurologic, skeletal, pigmentation, reproductive, or cutaneous abnormalities were reported in the Dutch families. The abstract explicitly states: “Although Lmx1a mouse mutants demonstrate neurological, skeletal, pigmentation and reproductive system abnormalities, no syndromic features were present in the participating subjects of either family.” (wesdorp2018heterozygousmissensevariants pages 1-2)

Disease-specific EQ-5D, SF-36, PROMIS, employment, educational, or psychosocial statistics are unavailable. Expected morbidity arises from impaired speech perception, communication, localization—especially with asymmetry—and possibly balance; severity depends on onset, progression, rehabilitation, and access to communication accommodations.

4. Genetic and molecular information

Causal gene and protein

LMX1A encodes a nuclear LIM-homeodomain transcription factor. The protein contains two cysteine-rich LIM domains that mediate protein–protein interactions and a homeodomain responsible for sequence-specific DNA binding. (lee2020novelgenotype–phenotypecorrelation pages 1-2)

Reported dominant variants

Reported heterozygous DFNA7-associated variants include:

  • NM_177398.4:c.290G>C, p.(Cys97Ser): missense; second LIM domain; disrupts a zinc-binding residue; segregated in a Dutch family and was absent from gnomAD in the 2018 analysis.
  • c.721G>C, p.(Val241Leu): de novo missense; DNA-binding homeodomain.
  • c.595A>G, p.(Arg199Gly): de novo missense; homeodomain; classified likely pathogenic in the source study; severe congenital asymmetric SNHL.
  • c.622C>T, p.(Arg208Ter): nonsense.
  • c.887dup, p.(Gln297ThrfsTer41): frameshift.
  • c.719A>G, p.(Gln240Arg): missense.
  • c.721G>A, p.(Val241Met): missense.
  • c.331del, p.(Gln111ArgfsTer7): frameshift, reported as novel in 2022.

Most variants were absent from the population resources consulted by the reporting laboratories. Current ClinVar assertions, transcript normalization, genome build, read evidence, and gnomAD frequency should nevertheless be rechecked variant by variant before clinical reporting. All are germline; no somatic DFNA7 mechanism is known. (lee2020novelgenotype–phenotypecorrelation pages 2-4, jo2022geneticloadof pages 4-5, jo2022geneticloadof pages 8-10, wesdorp2018heterozygousmissensevariants pages 4-6)

The p.Arg199Gly case was detected after abnormal newborn screening in a three-month-old boy. Reporter assays showed near-abolished transcriptional activity and no dominant-negative effect. The abstract states: “Further, our dominant LMX1A variant exerted pathogenic effects via haploinsufficiency rather than dominant-negative effect.” (PMID: 32840933; published September 2020; DOI: https://doi.org/10.1002/humu.24095). (lee2020novelgenotype–phenotypecorrelation pages 2-4, lee2020novelgenotype–phenotypecorrelation pages 1-2)

Genotype–phenotype relationship

Residual transcriptional activity appears related to clinical severity: p.Arg199Gly produced the largest functional deficit and congenital severe-to-profound loss, whereas p.Cys97Ser and p.Val241Leu produced moderate reductions and later progressive disease. This relationship is biologically coherent but remains based on very few variants and should not be treated as a validated predictive model. (lee2020novelgenotype–phenotypecorrelation pages 2-4, lee2020novelgenotype–phenotypecorrelation pages 1-2)

Modifiers, epigenetics, and structural variation

No validated modifier gene, methylation signature, histone alteration, or DFNA7-specific chromatin profile has been reported. A heterozygous 1q23.3–q24.1 deletion encompassing LMX1A in a separate patient supports dosage sensitivity, but large deletions may cause additional manifestations through neighboring genes. No recurrent DFNA7-specific translocation, inversion, aneuploidy, or copy-number syndrome is established. (wesdorp2018heterozygousmissensevariants pages 8-9)

5. Environmental and infectious information

DFNA7 is not caused by infection, radiation, pollution, diet, smoking, alcohol, or occupational exposure. No infectious trigger or zoonotic agent applies. Noise, ototoxic medication, aging, otitis, and other common causes may add independent hearing burden and should be assessed clinically, but their interaction with LMX1A has not been quantified. There are no DFNA7-specific CHEBI annotations beyond chemicals used in routine testing or treatment.

6. Mechanism and pathophysiology

Human causal chain

The best-supported chain is:

heterozygous LMX1A variant → impaired LIM-domain complex formation or homeodomain DNA binding → reduced transcriptional activity/haploinsufficiency → inadequate regulation or maintenance of cochleovestibular epithelial and neural programs → progressive dysfunction or loss of auditory/vestibular cells and ionic homeostasis → downsloping SNHL, asymmetry, and sometimes vestibular dysfunction. (wesdorp2018heterozygousmissensevariants pages 8-9, lee2020novelgenotype–phenotypecorrelation pages 1-2)

For later-onset alleles, one normal copy appears sufficient for gross embryonic development but insufficient for lifelong cochleovestibular maintenance. For severe alleles such as p.Arg199Gly, transcriptional function may fall below a developmental threshold, producing congenital disease. The 2018 authors summarized this uncertainty directly: “We propose that a single LMX1A wild-type copy is sufficient for normal development but insufficient for maintenance of cochleovestibular function.” (wesdorp2018heterozygousmissensevariants pages 1-2)

Developmental and cellular mechanisms from models

Mouse studies place Lmx1a upstream of sensory versus nonsensory epithelial segregation and vestibular/cochlear morphogenesis. Reciprocal negative regulation between Lmx1a and Lmo4 patterns sensory cristae, semicircular canals, utricle, endolymphatic duct, and basal cochlear hair cells. Other implicated networks include Wnt/Otx patterning, Delta–Notch-related sensory segregation, and regulation of Pax2, Fgf8, Sox2, Atoh1, Prox1, Hmx2/3, and Bmp6-dependent progenitors. These are model-derived pathways, not all proven direct targets in human DFNA7. (huang2018reciprocalnegativeregulation pages 1-2, chizhikov2021lmx1aandlmx1b pages 1-2, nichols2008lmx1aisrequired pages 11-12)

Recent mechanistic work showed that Lmx1a-null mice fail to differentiate a normal stria vascularis: marginal-cell proteins BSND and KCNQ1 and intermediate-cell marker CD44 are lost, pendrin/SLC26A4 expression expands abnormally, intermediate cells disappear, and the normal approximately 80–100 mV endocochlear potential is absent. This provides a plausible downstream ionic-homeostasis mechanism, but the study was published in 2025 and used recessive-null mice rather than human heterozygous DFNA7 tissue (DOI: https://doi.org/10.3389/fcell.2025.1537505). (renauld2025lmx1aisessential pages 1-2)

Suggested GO concepts include DNA-binding transcription-factor activity, transcriptional regulation, inner-ear development, sensory-organ morphogenesis, auditory-receptor-cell development, sensory-epithelium development, cell-fate specification, ion homeostasis, stria-vascularis development, and maintenance of sensory cells. The principal subcellular compartment is the nucleus.

Molecular profiling and advanced technologies

Single-cell qPCR in mouse cochlea identified an Lmx1a-positive type-I spiral ganglion neuron population at postnatal days P3, P8, and P12, distinct from Slc4a4- and Mfap4/Fzd2-marked populations. This suggests early molecular specification of auditory-afferent subtypes, but it does not establish that these neurons are the primary lesion in human DFNA7 (DOI: https://doi.org/10.3389/fnmol.2020.00083). (grandi2020singlecellrnaanalysis pages 1-2)

No DFNA7 patient-tissue transcriptome, proteome, metabolome, lipidome, spatial-transcriptomic atlas, CRISPR screen, or integrated patient multi-omics signature was found. There is no established immune, inflammatory, fibrotic, ischemic, or metabolic component.

7. Anatomical structures affected

The principal organ is the inner ear. Relevant sites are the cochlea and organ of Corti, cochlear sensory and nonsensory epithelia, stria vascularis, Reissner membrane, endolymphatic duct and sac, semicircular canals, utricle, saccule, and spiral ganglion. Human CT generally showed no major cochleovestibular malformation in later-onset heterozygous disease. (wesdorp2018heterozygousmissensevariants pages 1-2, renauld2025lmx1aisessential pages 1-2, nichols2008lmx1aisrequired pages 11-12)

Suggested mappings are:

  • UBERON: inner ear, cochlea, organ of Corti, stria vascularis, vestibular labyrinth, saccule, utricle, semicircular canal, spiral ganglion.
  • CL: inner/outer hair cell, sensory epithelial cell, nonsensory epithelial cell, strial marginal cell, strial intermediate cell/melanocyte-lineage cell, spiral ganglion neuron.
  • GO cellular component: nucleus and transcription-factor complex.

Hearing loss is usually bilateral but can be markedly asymmetric. Major secondary-organ involvement is not expected in human DFNA7.

8. Temporal development

Onset ranges from congenital/prelingual disease to childhood, adolescence, or adulthood. The 2023 review gives a first-to-sixth-decade range. Course is chronic and commonly progressive rather than episodic or remitting, although fluctuation was reported in one patient with possible coexisting Ménière disease. (jo2022geneticloadof pages 4-5, jo2022geneticloadof pages 8-10, alde2023autosomaldominantnonsyndromic pages 3-4)

Practical stages are not formally standardized but can be represented as: early high-frequency or asymmetric loss; broader-frequency moderate/severe loss with reduced speech perception; and advanced severe-to-profound loss potentially requiring cochlear implantation. Critical intervention windows include early childhood for congenital disease and any period when serial audiometry documents declining aided speech access. No spontaneous remission has been demonstrated.

9. Inheritance and population

Inheritance is autosomal dominant, with de novo disease recognized. Penetrance is likely age- and allele-dependent but has not been measured robustly. Expressivity is clearly variable in onset, symmetry, progression, vestibular involvement, and severity. Anticipation, germline mosaicism, founder effects, consanguinity effects, and carrier frequency have not been established. Consanguinity is not expected to be a major factor in dominant DFNA7, although biallelic LMX1A disease is a separate severe recessive phenotype. (wesdorp2018heterozygousmissensevariants pages 1-2, lee2020novelgenotype–phenotypecorrelation pages 2-4)

No population prevalence, incidence, sex ratio, or reliable ethnic/geographic enrichment is available. Published cases include Dutch and Korean clinical cohorts, but these ascertainment locations do not prove population enrichment. The two-center 2022 study found nine LMX1A patients from six families among a broader molecularly tested referral cohort; this is not a population-prevalence estimate. (jo2022geneticloadof pages 8-10)

10. Diagnostics

Clinical evaluation

Recommended assessment comprises history of onset and progression; three-generation pedigree; otoscopy; pure-tone air/bone audiometry; speech audiometry; tympanometry; otoacoustic emissions and auditory brainstem response when age or reliability warrants; and serial testing of each ear because asymmetry and progression are common. Vestibular history and examination should be followed by vHIT, caloric/rotary-chair testing, and cVEMP when imbalance or vertigo is present. Temporal-bone CT or MRI is used selectively to evaluate marked asymmetry, cochlear-implant anatomy, or alternative pathology, not as a molecular diagnostic test. (wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 4-6)

There is no blood chemistry, metabolite, circulating protein, biopsy, or histopathologic biomarker for DFNA7.

Genetic testing strategy

  1. Use a comprehensive hereditary-hearing-loss panel that includes LMX1A, with copy-number analysis and adequate coverage of relevant exons/splice regions.
  2. If negative or the presentation is atypical, use trio/family WES and segregation analysis; WES identified the founding dominant variants.
  3. Escalate unresolved cases to WGS to detect cryptic splice, regulatory, mitochondrial, and structural variants, although this is general hearing-loss practice rather than DFNA7-specific evidence.
  4. Confirm reportable variants by an orthogonal method when appropriate, review ClinVar/gnomAD, and apply current ACMG/AMP criteria with phenotype and segregation evidence.

Single-gene LMX1A sequencing is reasonable when the phenotype and family variant are known. CMA may detect a deletion encompassing LMX1A but is lower yield for sequence variants. Routine karyotype, FISH, mitochondrial testing, and repeat-expansion testing are not indicated unless another diagnosis is suspected. RNA studies can clarify suspected splice variants but are not routine DFNA7 diagnostics.

Differential diagnosis and screening

Differentials include other dominant nonsyndromic hearing-loss genes—especially KCNQ4, TECTA, WFS1, POU4F3, EYA4, ACTG1, MYO6, COCH, and MYO7A—as well as age/noise-related loss, congenital CMV, ototoxicity, Ménière disease, otosclerosis, and syndromic conditions initially presenting with isolated hearing loss. The combination of frequent asymmetry, progression, occasional vestibular dysfunction, and LMX1A variant is suggestive but not diagnostic by phenotype alone.

Universal newborn hearing screening can detect congenital severe alleles but will miss later-onset DFNA7. Once a familial pathogenic variant is established, offer cascade testing and baseline/serial audiometry to at-risk relatives, including those currently asymptomatic.

11. Outcome and prognosis

DFNA7 is not known to reduce survival or life expectancy, and disease-specific mortality is not reported. Morbidity is auditory and sometimes vestibular. Hearing may progress to severe or profound levels, but rate and final severity are allele- and person-dependent. Major prognostic features are age at onset, baseline thresholds, progression, asymmetry, speech discrimination, vestibular involvement, and access to timely amplification or implantation. No validated molecular prognostic biomarker exists beyond preliminary variant-function correlations. (lee2020novelgenotype–phenotypecorrelation pages 2-4, jo2022geneticloadof pages 8-10)

Spontaneous recovery is not expected. Functional outcomes can improve substantially with rehabilitation. In the 2022 series, one patient whose left ear progressed to profound loss underwent unilateral cochlear implantation and had significant speech-perception improvement at three and six months. (jo2022geneticloadof pages 8-10)

12. Treatment and applications

Current standard care

  • Hearing aids: first-line for aidable mild-to-severe loss; fit each ear according to thresholds and speech needs.
  • Cochlear implantation: consider for severe-to-profound loss with inadequate aided speech recognition. The available LMX1A evidence is favorable but limited to very small numbers.
  • Vestibular care: vestibular rehabilitation and disorder-specific management when objective dysfunction or imbalance is present.
  • Communication/rehabilitation: speech-language therapy where needed, assistive listening devices, classroom/workplace accommodations, captioning, and sign-language access according to patient preference.
  • Surveillance: long-term audiometry is important because progression and interaural divergence may alter device candidacy.

Suggested NCIT concepts are Hearing Aid, Cochlear Implantation, Audiologic Rehabilitation, Vestibular Rehabilitation, Speech Therapy, and Genetic Counseling; exact NCIT identifiers should be validated before database loading. (jo2022geneticloadof pages 8-10, alde2023autosomaldominantnonsyndromic pages 3-4)

Pharmacologic and advanced therapies

No drug, pharmacogenomic algorithm, surgery that corrects LMX1A dysfunction, cell therapy, ASO, siRNA, CRISPR treatment, or LMX1A gene therapy is approved or clinically validated. A search specifically for DFNA7/LMX1A trials found no relevant registered interventional study. The widely publicized 2024 hereditary-deafness gene-therapy advances concern biallelic OTOF/DFNB9, including seven reported trials, not dominant LMX1A disease; these results should not be extrapolated to DFNA7. (qi2026genetherapyfor pages 4-6)

For dominant haploinsufficiency, future strategies might include allele-agnostic augmentation or enhancement of residual LMX1A function, but developmental expression, nuclear transcriptional targeting, dosage control, delivery to multiple cochleovestibular cell types, and an uncertain treatment window remain substantial barriers.

13. Prevention

Primary prevention of a de novo or inherited pathogenic allele is not possible through lifestyle or vaccination. Reproductive options after identifying the family variant include genetic counseling, prenatal diagnosis, and preimplantation genetic testing, governed by patient values and local regulation. Predictive testing of minors can be clinically actionable because surveillance and hearing intervention are beneficial.

Secondary prevention consists of cascade testing, baseline audiology, serial monitoring, and prompt amplification or implantation. Tertiary prevention includes hearing conservation, avoidance of unnecessary ototoxic exposure, management of vestibular fall risk, and communication rehabilitation. These measures prevent additional disability rather than the underlying genotype. No vaccine or chemoprophylaxis applies.

14. Other species and natural disease

The principal comparative species is Mus musculus (NCBI Taxonomy 10090), with ortholog Lmx1a. Naturally occurring and induced mouse alleles include dreher, mutanlallemand, and belly-spot-and-deafness. Homozygous animals are deaf and display vestibular behaviors such as circling and head tossing, with absent endolymphatic ducts/semicircular canals, shortened cochlear ducts, sensory-patch abnormalities, and truncated Lmx1a protein. (DOI: https://doi.org/10.1371/journal.pone.0051065). (huang2018reciprocalnegativeregulation pages 1-2, nichols2008lmx1aisrequired pages 11-12)

These are hereditary laboratory-animal phenotypes, not a recognized contagious veterinary disease; breed-specific natural disease, VBO terms, zoonotic transmission, and cross-species infection are not applicable. Conservation of Lmx1-family auditory-development functions supports comparative utility, but species differ in dosage sensitivity.

15. Model organisms

Mouse genetic models

Recessive-null/dreher, spontaneous splice/deletion alleles, and conditional knockouts model Lmx1a loss. They reproduce deafness and vestibular dysfunction and reveal developmental abnormalities in the cochlea, vestibular labyrinth, stria vascularis, and central auditory structures. Relevant applications include studying sensory-epithelial segregation, ion homeostasis, hair-cell maintenance, vestibular morphogenesis, and interactions with Lmx1b/Lmo4/Wnt/BMP programs. (huang2018reciprocalnegativeregulation pages 1-2, renauld2025lmx1aisessential pages 1-2, chizhikov2021lmx1aandlmx1b pages 1-2, nichols2008lmx1aisrequired pages 11-12)

The major limitation is severity and inheritance mismatch: homozygous mouse nulls have profound multisystem developmental abnormalities, whereas human DFNA7 is heterozygous and usually nonsyndromic. Heterozygous mice had normal hearing through approximately three to four months in cited observations. Therefore, null-mouse anatomy supports biological plausibility but does not fully model human penetrance, progression, or asymmetry. (wesdorp2018heterozygousmissensevariants pages 8-9)

Cellular and in-vitro models

HEK293T luciferase assays quantify variant-specific LMX1A transcriptional activity and support haploinsufficiency and preliminary genotype–phenotype correlation. They cannot reproduce cochlear architecture, mechanical transduction, or long-term sensory-cell maintenance. Patient-derived iPSC inner-ear organoids, precise heterozygous knock-in animals, and longitudinal single-cell/spatial profiling would be higher-fidelity future models. (lee2020novelgenotype–phenotypecorrelation pages 2-4, lee2020novelgenotype–phenotypecorrelation pages 1-2)

Recent research and expert interpretation

The most important recent synthesis is the 2023 DFNA review, which places DFNA7 among more than 80 dominant hearing-loss loci and emphasizes long-term audiological follow-up to detect deterioration and trigger hearing-aid or cochlear-implant intervention. For DFNA7 specifically, however, the decisive human evidence remains the 2018 gene-discovery cohort, 2020 functional genotype–phenotype study, and 2022 tertiary-center series. (jo2022geneticloadof pages 8-10, alde2023autosomaldominantnonsyndromic pages 3-4)

A 2024 structural study of LMX1A homeodomain recognition of A/T-rich promoter motifs advances basic understanding of DNA binding but does not yet alter diagnosis or treatment (DOI: https://doi.org/10.1111/febs.17118). The latest mechanistic extension, published in 2025, identifies Lmx1a as essential for strial marginal-cell differentiation and endocochlear-potential generation in mice. Together these results strengthen a dual developmental-and-maintenance model but do not yet provide a therapeutic target validated in human DFNA7 tissue. (renauld2025lmx1aisessential pages 1-2)

Evidence limitations and curation cautions

DFNA7 evidence remains case-series level: no registry-scale natural-history study, prevalence estimate, prospective penetrance study, randomized treatment trial, patient-derived omics dataset, or validated environmental modifier exists. Several variants reported in research cohorts require current ClinVar and ACMG reassessment before clinical use. Mouse recessive-null findings must be labeled as model-organism evidence, and general hearing-loss recommendations must not be represented as DFNA7-specific efficacy data. The strongest directly supported knowledge-base assertions are the LMX1A association, autosomal-dominant/de novo inheritance, variable progressive SNHL with frequent asymmetry, occasional vestibular dysfunction, and haploinsufficiency mechanism. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A, wesdorp2018heterozygousmissensevariants pages 1-2, lee2020novelgenotype–phenotypecorrelation pages 2-4, jo2022geneticloadof pages 8-10)

References

  1. (wesdorp2018heterozygousmissensevariants pages 8-9): Mieke Wesdorp, P. A. M. de Koning Gans, M. Schraders, J. Oostrik, M. Huynen, H. Venselaar, A. Beynon, J. van Gaalen, Vitória Piai, N. Voermans, M. V. van Rossum, B. Hartel, Stefan H. Lelieveld, L. Wiel, B. Verbist, L. Rotteveel, M. V. van Dooren, P. Lichtner, H. Kunst, I. Feenstra, R. Admiraal, M. F. H. H. W. E. H. M. P. S. G. L. J. C. S. G. M. J. van Dooren de Gier Hoefsloot van der Schroeff Kant, M. V. van Dooren, H. D. de Gier, E. H. Hoefsloot, M. P. van der Schroeff, S. Kant, L. Rotteveel, S. Frints, J. Hof, R. Stokroos, E. Vanhoutte, R. Admiraal, I. Feenstra, H. Kremer, H. Kunst, R. Pennings, H. Yntema, A. V. van Essen, R. Free, J. S. Klein-Wassink, H. Yntema, L. Hoefsloot, R. Pennings, and H. Kremer. Heterozygous missense variants of lmx1a lead to nonsyndromic hearing impairment and vestibular dysfunction. Human Genetics, 137:389-400, May 2018. URL: https://doi.org/10.1007/s00439-018-1880-5, doi:10.1007/s00439-018-1880-5. This article has 43 citations and is from a peer-reviewed journal.

  2. (wesdorp2018heterozygousmissensevariants pages 1-2): Mieke Wesdorp, P. A. M. de Koning Gans, M. Schraders, J. Oostrik, M. Huynen, H. Venselaar, A. Beynon, J. van Gaalen, Vitória Piai, N. Voermans, M. V. van Rossum, B. Hartel, Stefan H. Lelieveld, L. Wiel, B. Verbist, L. Rotteveel, M. V. van Dooren, P. Lichtner, H. Kunst, I. Feenstra, R. Admiraal, M. F. H. H. W. E. H. M. P. S. G. L. J. C. S. G. M. J. van Dooren de Gier Hoefsloot van der Schroeff Kant, M. V. van Dooren, H. D. de Gier, E. H. Hoefsloot, M. P. van der Schroeff, S. Kant, L. Rotteveel, S. Frints, J. Hof, R. Stokroos, E. Vanhoutte, R. Admiraal, I. Feenstra, H. Kremer, H. Kunst, R. Pennings, H. Yntema, A. V. van Essen, R. Free, J. S. Klein-Wassink, H. Yntema, L. Hoefsloot, R. Pennings, and H. Kremer. Heterozygous missense variants of lmx1a lead to nonsyndromic hearing impairment and vestibular dysfunction. Human Genetics, 137:389-400, May 2018. URL: https://doi.org/10.1007/s00439-018-1880-5, doi:10.1007/s00439-018-1880-5. This article has 43 citations and is from a peer-reviewed journal.

  3. (lee2020novelgenotype–phenotypecorrelation pages 2-4): Sang‐Yeon Lee, Jin Hee Han, Marge Carandang, Min Young Kim, Bonggi Kim, Nayoung Yi, Jinho Kim, Bong Jik Kim, Doo‐Yi Oh, Ja‐Won Koo, Jun Ho Lee, Seung‐Ha Oh, and Byung Yoon Choi. Novel genotype–phenotype correlation of functionally characterized lmx1a variants linked to sensorineural hearing loss. Sep 2020. URL: https://doi.org/10.1002/humu.24095, doi:10.1002/humu.24095. This article has 23 citations and is from a domain leading peer-reviewed journal.

  4. (jo2022geneticloadof pages 8-10): Hyung Dong Jo, Jin Hee Han, So Min Lee, Dong Hwa Choi, Sang-Yeon Lee, and Byung Yoon Choi. Genetic load of alternations of transcription factor genes in non-syndromic deafness and the associated clinical phenotypes: experience from two tertiary referral centers. Biomedicines, 10(9):2125, Aug 2022. URL: https://doi.org/10.3390/biomedicines10092125, doi:10.3390/biomedicines10092125. This article has 11 citations.

  5. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A): Open Targets Query (autosomal dominant nonsyndromic hearing loss 7-LMX1A, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  6. (alde2023autosomaldominantnonsyndromic pages 3-4): Mirko Aldè, Giovanna Cantarella, Diego Zanetti, Lorenzo Pignataro, Ignazio La Mantia, Luigi Maiolino, Salvatore Ferlito, Paola Di Mauro, Salvatore Cocuzza, Jérôme René Lechien, Giannicola Iannella, Francois Simon, and Antonino Maniaci. Autosomal dominant non-syndromic hearing loss (dfna): a comprehensive narrative review. Biomedicines, 11:1616, Jun 2023. URL: https://doi.org/10.3390/biomedicines11061616, doi:10.3390/biomedicines11061616. This article has 65 citations.

  7. (lee2020novelgenotype–phenotypecorrelation pages 1-2): Sang‐Yeon Lee, Jin Hee Han, Marge Carandang, Min Young Kim, Bonggi Kim, Nayoung Yi, Jinho Kim, Bong Jik Kim, Doo‐Yi Oh, Ja‐Won Koo, Jun Ho Lee, Seung‐Ha Oh, and Byung Yoon Choi. Novel genotype–phenotype correlation of functionally characterized lmx1a variants linked to sensorineural hearing loss. Sep 2020. URL: https://doi.org/10.1002/humu.24095, doi:10.1002/humu.24095. This article has 23 citations and is from a domain leading peer-reviewed journal.

  8. (wesdorp2018heterozygousmissensevariants pages 4-6): Mieke Wesdorp, P. A. M. de Koning Gans, M. Schraders, J. Oostrik, M. Huynen, H. Venselaar, A. Beynon, J. van Gaalen, Vitória Piai, N. Voermans, M. V. van Rossum, B. Hartel, Stefan H. Lelieveld, L. Wiel, B. Verbist, L. Rotteveel, M. V. van Dooren, P. Lichtner, H. Kunst, I. Feenstra, R. Admiraal, M. F. H. H. W. E. H. M. P. S. G. L. J. C. S. G. M. J. van Dooren de Gier Hoefsloot van der Schroeff Kant, M. V. van Dooren, H. D. de Gier, E. H. Hoefsloot, M. P. van der Schroeff, S. Kant, L. Rotteveel, S. Frints, J. Hof, R. Stokroos, E. Vanhoutte, R. Admiraal, I. Feenstra, H. Kremer, H. Kunst, R. Pennings, H. Yntema, A. V. van Essen, R. Free, J. S. Klein-Wassink, H. Yntema, L. Hoefsloot, R. Pennings, and H. Kremer. Heterozygous missense variants of lmx1a lead to nonsyndromic hearing impairment and vestibular dysfunction. Human Genetics, 137:389-400, May 2018. URL: https://doi.org/10.1007/s00439-018-1880-5, doi:10.1007/s00439-018-1880-5. This article has 43 citations and is from a peer-reviewed journal.

  9. (jo2022geneticloadof pages 4-5): Hyung Dong Jo, Jin Hee Han, So Min Lee, Dong Hwa Choi, Sang-Yeon Lee, and Byung Yoon Choi. Genetic load of alternations of transcription factor genes in non-syndromic deafness and the associated clinical phenotypes: experience from two tertiary referral centers. Biomedicines, 10(9):2125, Aug 2022. URL: https://doi.org/10.3390/biomedicines10092125, doi:10.3390/biomedicines10092125. This article has 11 citations.

  10. (huang2018reciprocalnegativeregulation pages 1-2): Yanhan Huang, Jennifer Hill, Andrew Yatteau, Loksum Wong, Tao Jiang, Jelena Petrovic, Lin Gan, Lijin Dong, and Doris K. Wu. Reciprocal negative regulation between lmx1a and lmo4 is required for inner ear formation. The Journal of Neuroscience, 38:5429-5440, Jun 2018. URL: https://doi.org/10.1523/jneurosci.2484-17.2018, doi:10.1523/jneurosci.2484-17.2018. This article has 23 citations.

  11. (iskusnykh2026anlmx1aballelic pages 1-2): Igor Y. Iskusnykh, Bernd Fritzsch, Ebenezer N. Yamoah, Ekaterina Y. Steshina, and Victor V. Chizhikov. An lmx1a/b allelic series reveals the role of lmx1 genes in cochlear nuclei development. Cell and Tissue Research, Apr 2026. URL: https://doi.org/10.1007/s00441-026-04064-7, doi:10.1007/s00441-026-04064-7. This article has 1 citations and is from a peer-reviewed journal.

  12. (renauld2025lmx1aisessential pages 1-2): Justine M. Renauld, Igor Y. Iskusnykh, Ebenezer N. Yamoah, Richard J. H. Smith, Corentin Affortit, David Z. He, Huizhan Liu, David Nichols, Judith Bouma, Mahesh K. Nayak, Xin Weng, Tianli Qin, Mai Har Sham, Victor V. Chizhikov, and Bernd Fritzsch. Lmx1a is essential for marginal cell differentiation and stria vascularis formation. Frontiers in Cell and Developmental Biology, Mar 2025. URL: https://doi.org/10.3389/fcell.2025.1537505, doi:10.3389/fcell.2025.1537505. This article has 9 citations.

  13. (nichols2008lmx1aisrequired pages 11-12): David H. Nichols, Sarah Pauley, Israt Jahan, Kirk W. Beisel, Kathleen J. Millen, and Bernd Fritzsch. Lmx1a is required for segregation of sensory epithelia and normal ear histogenesis and morphogenesis. Cell and Tissue Research, 334:339-358, Nov 2008. URL: https://doi.org/10.1007/s00441-008-0709-2, doi:10.1007/s00441-008-0709-2. This article has 155 citations and is from a peer-reviewed journal.

  14. (chizhikov2021lmx1aandlmx1b pages 1-2): Victor V. Chizhikov, Igor Y. Iskusnykh, Nikolai Fattakhov, and Bernd Fritzsch. Lmx1a and lmx1b are redundantly required for the development of multiple components of the mammalian auditory system. Jan 2021. URL: https://doi.org/10.1016/j.neuroscience.2020.11.013, doi:10.1016/j.neuroscience.2020.11.013. This article has 57 citations and is from a domain leading peer-reviewed journal.

  15. (grandi2020singlecellrnaanalysis pages 1-2): Fiorella Carla Grandi, Lara De Tomasi, and Mirna Mustapha. Single-cell rna analysis of type i spiral ganglion neurons reveals a lmx1a population in the cochlea. Frontiers in Molecular Neuroscience, May 2020. URL: https://doi.org/10.3389/fnmol.2020.00083, doi:10.3389/fnmol.2020.00083. This article has 32 citations.

  16. (qi2026genetherapyfor pages 4-6): Yu Qi, Fangzhi Tan, Maoli Duan, and Ling Lu. Gene therapy for non-syndromic hearing loss. Head and Neck Diseases Conflux, 2(1):e345, Mar 2026. URL: https://doi.org/10.71321/703b4949, doi:10.71321/703b4949. This article has 0 citations.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 13
Resolved 13
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 13
On topic 3
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 3
Resolved 3
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0

Every term resolved, and every label the report gave matched.